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Abstract 
Congestive heart failure (CHF) is a common cardiac condition in cats, which usually results 
from primary cardiomyopathy (CM). It is a complex syndrome with many pathophysiological 
processes involved. The aim of this study was to investigate two aspects i.e. cardiovascular 
renal axis disorder (CvRD) and systemic inflammatory response in feline CHF due to primary 
CM.    
The study population included 25 CHF cats, 12 asymptomatic CM cats and 20 healthy control 
cats. Two panels of biomarkers were tested as reflections of CvRD (cardiac biomarker NT-
proBNP, renal biomarker SDMA and creatinine) and inflammatory response (7 acute phase 
proteins) respectively. The biomarker expressions in the three cat groups, correlations between 
the biomarkers and selected clinical variables, and risk factors in the CHF cats were analysed. 
Following the baseline studies, pilot longitudinal studies were carried out to investigate 
biomarker changes in 12 CHF cats over 12 months.  
The results showed both CvRD and systemic inflammatory response occurred in feline CHF. 
Considering the high prevalence of CvRD, it is recommended that the novel renal biomarker 
SDMA should be used as a renal function monitor in CHF management. Moreover, similar to 
NT-proBNP, it potentially carries prognostic value for feline CHF. Three acute phase proteins 
(APPs) showed significant changes in CHF (i.e. LRG1, ceruloplasmin and SAA) and may help 
to better understand the pathogenesis of feline CHF as well as predict the disease outcome. 
Positive correlations between APPs and cardiac variables suggested their intrinsic involvement 
in cardiac disease. In addition, serum AGP appeared to carry independent prognostic value for 
feline CHF. In combination with other clinical information, the APPs may be promising novel 
clinical biomarkers for feline CHF. Additionally, some clinical parameters were found to have 
the ability to stage CM and provide prognostic information. Preliminary results from 
longitudinal measurements showed that NT-proBNP measurements persistently higher than 
1500 pmol/l, or a single SDMA measurement higher than 20 ug/dl appeared to be associated 
with a poorer outcome. Most APP expressions appeared to decrease over time. Future work 
will be needed to consolidate these findings. 
This study has identified novel CvRD and inflammatory biomarkers involved in a feline CHF 
study population. Current findings can be potentially implemented in future research and in 
clinical management of feline CHF and CM. 
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Highlights of the Study  
 
• This is the first study reporting CvRD in cats with CHF due to primary CM and that   
            SDMA and NT-proBNP both potentially have prognostic value in feline CHF. 
• This is the first study demonstrating APPs involved in feline CHF; moreover, serum  
            AGP appeared to be an independent predictor for poor prognosis in CHF. 
• This is the first study reporting LRG1 expression in cats. 
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Chapter 1: Introduction 
1.1 Feline Cardiomyopathies  
Cardiomyopathies (CMs) are common cardiac diseases in cats; they are defined as myocardial 
diseases associated with cardiac dysfunction (Richardson et al., 1996). Traditionally, based on 
anatomical and functional abnormalities, primary CMs are categorized into hypertrophic 
cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), dilated cardiomyopathy (DCM), 
arrhythmogenic right ventricular cardiomyopathy (ARVC) and unclassified cardiomyopathy 
(UCM) (Ferasin et al., 2003; Fox et al., 2000).  
Initial identification of feline CM can be traced back to the 1970s (Liu, 1970). In the early 
1980s feline CM was first proposed to be a comparable animal model for human HCM with 
preserved ejection fraction (Liu and Tilley, 1980). Subsequent studies on feline CM have been 
mainly focused on HCM, with other forms of CMs relatively under-investigated. Today, the 
majority of our understanding of feline CM is largely based on the HCM phenotype. 
1.1.1 Aetiology and Pathogenesis 
The aetiology and pathogenesis of feline CM, particularly idiopathic CM, remains unclear, 
however familial heritability has been observed in both feline and human CM patients. In 
human medicine, HCM is considered as a genetic heart disease caused by mutation of 
sarcomeric protein encoding genes. There are 1500 known mutations of 11 genes that have 
been identified to associate with human HCM (Maron and Fox, 2015). Similar to human, feline 
HCM may also have a genetic cause associated with heart muscle sarcomere mutations. 
Causative mutations of myosin binding protein C3 (MYBPC3) have been identified in the 
Maine Coon (Meurs et al., 2005; Fries et al., 2008) and Ragdoll cats (Meurs et al., 2007; 
Borgeat et al., 2014a). There are other cat breeds found to have familial HCM, including British 
Short Hair (Granstrom et al., 2011), Sphynx (Silverman et al., 2012) and Norwegian Forest 
cats (Marz et al., 2015). Familial inherited RCM has also been reported in humans, and 
accounted for one third of total RCM cases in one study (Kaski et al., 2008). In cats, so far 
there is no causative mutation identified for other CM phenotypes but familial inheritance or a 
genetic cause has been proposed in previous DCM and ARVC studies (Lawler et al., 1993; Fox 
et al., 2000). The significance of genetic aetiology in feline CM is yet to be fully understood, 
however it has been hypothesized that different clinical CM phenotypes may be caused by 
variations of the mutations within specific functional domains of the sarcomeric disease gene 
(Côté et al., 2011b).  
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Apart from genetic factors, other causative factors have been reported in feline CM such as 
taurine deficiency associated DCM (Lawler et al., 1993) and myocardial change secondary to 
systemic diseases such as hyperthyroidism and hypertension (Ware, 2011b). Recently, there 
was an interesting report of transient myocardial thickening (TMT) and CHF in cats; this has 
been described as a reversible condition, most likely due to myocardial acute inflammation or 
oedema in response to some antecedent events such as general anaesthesia or traumatic injuries, 
although no definitive evidence has been proven for this hypothesis (Novo Matos et al., 2018). 
Metabolic disorders such as obesity and diabetes mellitus have been found to cause CMs in 
human (Alpert, 2001; Boudina and Abel, 2010). As the two species share many similarities in 
metabolic disorders, the cat has been proposed to be a useful model for research into human 
obesity and diabetes (Hoenig, 2012). In cats, so far obesity and diabetes mellitus have not been 
proven as CM causes, but certain links were established in previous studies. For example, 
obesity has been found as a risk factor in inherited HCM in the Maine Coon breed; a theory of 
environmental factors such as nutritional modification of genes has been hypothesized to 
explain the diverse presentations of familiar inherited HCM in the Maine Coon (Freeman et al., 
2013). A later randomised trial in HCM cats suggested diet may play a role in the disease 
(Freeman et al., 2014). Differential serum fatty acid profiles were observed in HCM cats 
compared with the normal controls, which suggested HCM cats may have altered fatty acid 
metabolism potentially linked with cardiovascular conditions (Hall et al., 2014a). Also in 
previous studies, body weight and body condition score have been found to be associated with 
the incidence and prognosis of HCM (Payne et al., 2015a; Finn et al., 2010). A few studies 
have investigated the links between diabetes mellitus and cardiac dysfunction in cats. A recent 
publication demonstrated reduced diastolic function occurred in diabetic cats, irrespective of 
diabetic control status; the diastolic dysfunction appeared to progress in those cats in a 6 month 
follow up (Pereira et al., 2017). Another study has shown heart failure was common in cats 
with diabetes mellitus and was responsible for approximately 40% of deaths in diabetic cats in 
their study population (Little et al., 2008). Another endocrinological condition, acromegaly 
(hypersomatotropism) is known to be associated with myocardial hypertrophy in cats and the 
echocardiographic changes were found to be reversible with effective treatment of the 
acromegaly (Borgeat et al., 2018).  
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1.1.2 Pathology and Histopathology 
The macroscopic features of each CM phenotype are relatively distinguishable, however, 
despite different phenotypic diagnosis, the histopathological changes of feline CM are largely 
similar. In most of the feline CMs, myocardial and extracellular matrix (ECM) remodelling, 
coronary arteriosclerosis and inflammatory cell infiltration are commonly reported 
histopathological features (Fox, 2003; Fox, 2004; Kittleson et al., 1999; Aupperle et al., 2011; 
Khor et al., 2015). 
The gross pathological findings in HCM are characterized by variable degrees of left 
ventricular (LV) hypertrophy, papillary muscle hypertrophy and reduced LV cavity diameter 
(Fox, 2003). A moderately to severely dilated left atrium (LA) is commonly seen (Fox, 2003). 
Histopathological hallmarks of HCM have been described as myofibre disarray, small 
intramural coronary arteriosclerosis, interstitial fibrosis and replacement fibrosis (Kittleson et 
al., 1999; Liu et al., 1993). In Liu’s study in 1993, 30% of HCM cats had evidence of myofibre 
disarray and, 74% had abnormal intramural coronary arteries, while in Fox’s later study, more 
than 60% of cats had the above two abnormalities and concurrent ECM remodelling (Fox et 
al., 1995). Myocardial collagen deposition and inflammatory cell infiltration has been found in 
pre-clinical HCM cats, which may suggest ECM remodelling and inflammation occur at an 
early stage of the disease (Khor et al., 2015). Male cats, which are reported to be more 
predisposed to HCM, have myocardial changes in a pro-inflammatory stage even when they 
are free from overt cardiac disease (Fonfara et al., 2015).  
RCM shares many similarities with HCM (Spalla et al., 2016) and can be further classified in 
to a myocardial form (Fox et al., 2014) and an endocardial form (Fox, 2004). Macroscopically, 
bi-atrial dilation can be seen in both forms, and there is no apparent myocardial hypertrophy 
(Fox et al., 2014). Endocardial RCM is characterised by endocardial and myocardial interstitial 
fibrosis in the left ventricle, presence of inflammatory cells consistent with endomyocarditis, 
and occasional arteriosclerosis in the intramural coronary arterioles (Fox, 2004; Kimura et al., 
2016). In the myocardial form of RCM, myofibre disarray and replacement fibrosis of the 
myocardium were reported features (Fox et al., 2014). 
DCM is characterized typically by a dilated LA and ventricle and in the more advanced cases 
all four cardiac chambers are dilated (Côté et al., 2011c). Histopathological findings of DCM 
have been described as variable; myocytolysis, myofibre degeneration and fibrosis may be 
observed (Côté et al., 2011c). 
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ARVC is uncommon in cats. The most consistent post-mortem cardiac change in ARVC is 
right ventricular dilation (Harvey et al., 2005; Fox et al., 2000). Microscopically, it is 
characterized by cardiomyocyte degeneration, adipose and fibrous tissue replacement of the 
myocardium and inflammatory cell infiltration in the right ventricle. Myocarditis can be a 
common feature. Similar histopathological changes were also observed in the left ventricle in 
most ARVC cats in Fox and colleagues’ study (Fox et al., 2000). 
UCM has been defined as a type of CM that cannot readily fit any of the above classifications, 
and may possess a combination of non-specific changes (Ferasin, 2009). So far no specific 
histopathological changes are reported for UCM.  
Phenotype transition of feline CM may occur; notably a DCM may be an end-stage 
consequence of other CM types such as a primary HCM (Côté et al., 2011b). This confounds 
accurate macroscopic classification and thus histopathological characterization for individual 
CM phenotypes. Considering this issue, possibly a broad term, such as feline CM, would be 
more appropriate to use when describing the disease.
 
1.1.3 Clinical Presentation, Diagnosis and Prognosis 
The clinical presentation and progression of CM is variable among individual cats. While a 
large proportion of affected cats remain asymptomatic, other cats develop significant clinical 
consequences including CHF, arterial thromboembolism (ATE) and arrhythmia associated 
sudden death. The symptomatic patients generally have a much poorer prognosis compared 
with asymptomatic ones (Atkins et al., 1992). Common clinical findings include a heart 
murmur, audible gallop sounds (the 3rd and 4th heart sounds, which are not normally audible in 
small animals), arrhythmias, pulse deficit, tachypnoea, dyspnoea, tachycardia, syncope, 
collapse, hypothermia, anorexia, lethargy and signs of pain. Most of the above signs are non-
specific, although certain parameters have been proven to associate with disease outcome (Côté 
et al., 2011b). Primarily focusing on the HCM phenotype, the disease epidemiology, diagnostic 
and prognostic features are discussed below: 
HCM 
HCM is the most common form of feline CM, which represented 57.5% of cases in one study 
of 106 CM cats (Ferasin et al., 2003). The prevalence of HCM in clinically healthy cats is 
reported to be approximately 15% (Payne et al., 2015b; Paige et al., 2009; Wagner et al., 2010). 
  
21 
 
The mean age at presentation is reported as around 5-6 years, with male cats over-represented 
(Ferasin et al., 2003; Payne et al., 2015b; Rush et al., 2002; Atkins et al., 1992). The Maine 
Coon and Ragdoll cats with homozygous MYBPC3 mutations have been shown to have earlier 
onset and a more severe form of HCM (Kittleson et al., 1999; Meurs et al., 2007). Common 
diagnostic criteria of HCM are increased LV wall thickness > 6 mm at the end of diastole and/or 
evidence of focal hypertrophy in the ventricles, and papillary muscle hypertrophy on 2 
dimensional (2D) echocardiography (Ferasin, 2009; Payne et al., 2015b). LA enlargement is a 
common echo feature in HCM cats (48.8%), especially in the advanced stage of disease (Payne 
et al., 2010). The most common physical examination findings in asymptomatic HCM cats are 
a systolic heart murmur and/or gallop sounds (Côté et al., 2011b). When CHF develops, 
dyspnoea is usually the first obvious clinical sign (Côté, 2017). The most common 
electrocardiographic (ECG) finding with HCM is left anterior fascicular block and intermittent 
ventricular premature complexes (VPCs) (Ferasin et al., 2003).  
Hypertrophic obstructive cardiomyopathy (HOCM) is a form of HCM when there is narrowing 
of the LV outflow tract and also frequently has systolic anterior motion (SAM) of the septal 
cusp of the mitral valve (Ferasin, 2009; Côté et al., 2011b). SAM is usually associated with LV 
outflow tract obstruction (LVOTO), which is possibly due to focal hypertrophy of the 
interventricular septum (IVS), abnormal anatomy of the mitral valve apparatus or physiological 
sympathetic activation (Abbott, 2010). It has been considered as a positive outcome indicator 
in feline HCM (Fox et al., 1995; Payne et al., 2010). 
Apart from CHF (which will be discussed in Section 1.2), another common clinical outcome 
of HCM is ATE. Incidence of ATE in HCM cats has been reported as ranging from 12-17% 
(Rush et al., 2002; Atkins et al., 1992; Peterson et al., 1993). LA enlargement and dysfunction 
appear to be major risk factors for ATE in HCM cats (Laste and Harpster, 1995; Payne et al., 
2015b). In fact, ATE is not unique to HCM; LA enlargement and evidence of increased 
thromboembolic risk (i.e. spontaneous echo contrast) are also seen in feline RCM, UCM and 
DCM (Peck et al., 2016). Acute lameness (especially hindlimbs) and pain are common clinical 
signs for ATE. Similar to CHF, the long term prognosis of ATE is generally poor (Côté et al., 
2011d). 
The current treatment principle for feline HCM is mainly targeting the symptomatic cases, i.e. 
CHF, ATE or arrhythmia. In asymptomatic HCM cats, therapeutic intervention is controversial 
(Ferasin, 2009). Diltiazem, atenolol and angiotensin converting enzyme (ACE) inhibitors have 
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been advocated for use in asymptomatic HCM cats, but there is lack of scientific evidence to 
prove their definite benefits (Ferasin, 2009). Anti-platelet medication clopidogrel may be more 
justified to use in asymptomatic CM cases to reduce the risk of future thrombotic events when 
there is evidence of LA enlargement, spontaneous echo contrast or an intra-cardiac thrombus 
(Hogan et al., 2015). Treatment of CHF will be discussed in Section 1.2.3. 
The prognosis for HCM largely depends on the underlying cause and whether the cats are 
symptomatic (Spalla et al., 2016; Atkins et al., 1992; Rush et al., 2002). CM secondary to 
hyperthyroidism or systemic hypertension have better outcomes (Spalla et al., 2016). Reported 
median survival time (MST) in asymptomatic HCM ranges from 1129-3671 days. Cats with 
ATE had a shorter MST, ranging from 61-184 days (Atkin et al., 1992; Rush et al., 2002; Payne 
et al., 2010). Survival of HCM cats with CHF is discussed in Section 1.2.4. 
Other CM Phenotypes  
The other feline CM phenotypes include RCM, DCM, ARVC and UCM. The clinical signs and 
treatment strategy share a lot of common features with symptomatic HCMs. Regarding disease 
epidemiology, presentation and prognosis, each of these have some unique characteristics.  
RCM is the second most common CM in cats, accounting for 15-20% of total CM according 
to previous studies (Ferasin et al., 2003; Locatelli et al., 2018). The echocardiographic 
diagnosis of RCM is characterized by severely dilated LA or bi-atrial dilation, usually with 
endocardial fibrotic lesions and impaired diastolic function (Ferasin, 2009). Most RCM cats at 
diagnosis were symptomatic with respiratory distress as the most common clinical presentation 
(Ferasin et al., 2003; Locatelli et al., 2018) and it appears to be a more severe form of CM 
compared with HCM (Côté et al., 2011b). Reported MST of feline RCM is between 132-466 
days (Ferasin et al., 2003; Spalla et al., 2016; Locatelli et al., 2018) and once respiratory distress 
develops the prognosis is very poor (Locatelli et al., 2018). 
DCM is reported to represent 4.4-10.4% of total CM in cats (Ferasin et al., 2003; Locatelli et 
al., 2018). The echocardiographic diagnostic criteria are severe LV dilation with reduced LV 
systolic function (Ferasin et al., 2003). Taurine deficiency plays a role in feline DCM (Pion et 
al., 1987), but it cannot fully explain the aetiology in all cases (Côté et al., 2011c). The 
incidence of CHF in DCM is high, and in one previous study cardiomegaly and CHF occurred 
in 100% of DCM cats (Ferasin et al., 2003); the prognosis for DCM is grave (Ferasin et al., 
2003; Côté et al., 2011c). One study has shown treatment with pimobendan improved the MST 
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in DCM cats to 49 days; without pimobendan, the MST was only 12 days (Hambrook and 
Bennett, 2012). 
ARVC is an uncommon phenotype in cats and one previously reported incidence was 0.5% of 
feline CM cases (Locatelli et al., 2018); male cats appear to be over-represented (Fox et al., 
2000; Harvey et al., 2005). The cardinal echocardiographic feature of ARVC is right ventriclar 
dilation with thinning of the myocardium, right atrial dilation and an apical ventricular 
aneurism may also be present (Fox et al., 2000). ARVC is most commonly associated with 
right sided CHF, and syncope may be observed in affected cats. Arrhythmia is common in 
feline ARVC, and variable supraventricular and/or ventricular arrhythmias and 3rd degree 
atrioventricular (AV) block have been identified (Fox et al., 2000; Harvey et al., 2005). The 
reported prognosis for ARVC in cats is very poor (Fox et al., 2000).  
UCM has been defined as those cardiomyopathies that cannot easily be recognized and 
categorized into the current known phenotypes based on echocardiographic criteria (Ferasin et 
al., 2003). The reported incidence is 2.9-10.4% of all feline CMs (Ferasin et al., 2003; Locatelli 
et al., 2018). It should be noted that this phenotype may be a transition phenotype to others 
(Côté et al., 2011b). The reported MST of UCM cats was 925 days (Ferasin et al., 2003).
Copyright by Mengmeng Liu 2018. All Rights Reserved. 
1.2 Feline Congestive Heart Failure 
The first documentation of heart failure in human history goes back to 2000 BC and cardiogenic 
congestion was recorded in both ancient Egypt and China (Ferrari et al., 2016). For quite a long 
period of time, heart failure was considered simply as a circulatory disorder, in which the heart 
could not pump out enough blood to satisfy the body’s requirements. Nowadays, by definition, 
heart failure is considered to be a complex clinical syndrome in which the heart fails to produce 
enough cardiac output to meet the body’s metabolic demands or is compromised to achieve so 
at the cost of increased filling pressure (Ware, 2011a). 
1.2.1 Aetiology and Pathogenesis 
Congestive heart failure (CHF) is characterized by venous congestion or fluid accumulation in 
body cavities due to high cardiac filling pressures (Côté et al., 2011a). Based on the nature of 
the primary cause, heart failure can be classified into systolic failure (also called reduced 
ejection fraction) or diastolic failure (also called preserved ejection fraction). In feline medicine, 
the most common cause of CHF is one of the primary CMs, and they are often associated with 
diastolic failure (Côté et al., 2011a).  
The pathogenesis of heart failure is complex and involves a number of pathophysiological 
mechanisms such as inflammation, neurohormonal activation and myocardial remodelling 
(Dick and Epelman, 2016; Kemp and Conte, 2012). Neurohormonal activation is considered 
as one of the most important responses, particularly activation of the sympathetic nervous 
system (SNS) and renin-angiotensin-aldosterone-system (RAAS) activation (Hartupee and 
Mann, 2017). SNS and RAAS activation is a compensatory response when cardiac function is 
impaired; however, in the long term they may lead to circulatory congestion and myocardial 
remodelling. The SNS responds earlier in cardiac decompensation and decreased cardiac 
output or pressure change sensed by arterial baroreceptors can activate the SNS to increase 
heart rate and contractility in order to improve cardiac output (Côté et al., 2011a). Activation 
of the RAAS pathway causes sodium and water retention to increase renal blood flow through 
a series of mechanisms. It can also induce myocardial inflammation and remodelling through 
cellular activation and cytokine release (Sciarretta et al., 2009). Neurohormonal responses also 
occur in the kidney and peripheral vasculature, which decrease renal sensitivity to natriuretic 
peptide, increase vasopressin and endothelin expression and impair nitric oxide (NO) release 
in the peripheral vasculature, resulting in vasoconstriction (Chinnaiyan et al., 2005). 
Inflammation has been considered to play a key role in heart failure and more details are 
discussed in Section 1.4. Overall, the neurohormonal and inflammatory responses are both 
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consequences of and causes for progression in heart failure, with anatomical cardiac 
remodelling occurring at the same time (Van Linthout and Tschope, 2017).  
The myocardial remodelling in heart failure includes maladaptive cardiomyocyte hypertrophy 
and apoptosis, myocardial fibrosis, remodelling of the ECM and regional ischemia (Cohn et 
al., 2000; Fonfara et al., 2012). In a recent study of feline cardiac pathology, myofibre disarray, 
interstitial fibrosis, sub-endocardial fibrosis and occasional intramural arteriosclerosis were 
identified in CHF hearts (Wilkie et al., 2015). 
 
1.2.2 Classification, Clinical Presentations and Diagnosis 
Classification of CHF in small animals is mainly based on the clinical signs of the patient (Fox 
et al., 1999). The International Small Animal Cardiac Health Council (ISACHC) classification 
is one of the most common methods used in staging feline CHF (Finn et al., 2010). There are 
three major classes in this system, depending on whether the patient is symptomatic or not. 
CHF is classified as asymptomatic (Class I), mild to moderate CHF (Class II) or; severe CHF 
(Class III). Sub-classification is based on whether there is evidence of cardiac remodelling 
(class Ia vs. class Ib), or to what extent the clinical signs affect the patient’s quality of life and 
whether home management is sufficient (class IIIa) or hospital stabilization is required (class 
IIIb) (Fox et al., 1999).  
Antecedent events such as recent fluid therapy, general anaesthesia or recent corticosteroid 
administration may trigger CHF development in CM cats (Rush et al., 2002). The common 
clinical presentations of feline CHF include pulmonary oedema, pleural effusion, ascites, 
jugular distension and pericardial effusion (Ferasin and Defrancesco, 2015). Typically, feline 
CM induces left sided CHF, which most commonly presents as pulmonary oedema and/or 
pleural effusion (Côté et al., 2011a). Dyspnoea and tachypnoea are considered as cardinal 
physical examination findings of acute onset cardiac decompensation in cats (Ferasin and 
Defrancesco, 2015). Signs of dyspnoea, such as paradoxical breathing, are the most commonly 
observed abnormalities by the owners (Côté, 2017). Open-mouth breathing or labouring 
breathing are also common descriptions. The respiratory rate has been found to increase in 
CHF cats compared with cats with asymptomatic CM (Ljungvall et al., 2014). A resting or 
sleeping respiratory rate higher than 30 breaths per minute in a cat with cardiac disease warrants 
investigation for CHF (Ljungvall et al., 2014; Porciello et al., 2016). Heart rate changes in CHF 
cats can be highly variable according to previous publications; tachycardia should theoretically 
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be more common but this was an absent feature in many CHF cats (Dickson et al., 2018; Rush 
et al., 2002; Smith and Dukes-McEwan, 2012). Heart murmurs are often absent or inconsistent 
in CHF (Smith and Dukes-McEwan, 2012; Goutal et al., 2010) and do not appear to be a 
reliable indicator for significant cardiac disease in cats (Abbott, 2010). Gallop sounds, due to 
increased ventricular stiffness have been shown to have more pathognomonic significance in 
feline cardiac disease. Previous studies have suggested that 20%-50% of CHF cats have gallop 
sounds and their presence has been found to be a mortality risk factor in feline CHF (Payne et 
al., 2015b). Hypothermia is also reported in CHF cats, especially at initial presentation 
(Dickson et al., 2018; Goutal et al., 2010). Arrhythmias can be a concurrent problem with feline 
CHF, with ventricular premature complex, atrial fibrillation and ventricular tachycardia are 
common examples (Smith and Dukes-McEwan, 2012; Côté et al., 2004). Other signs may 
include pale mucous membrane, weak femoral pulses, abdominal distension, general weakness, 
anorexia and lethargy (Côté et al., 2011a). 
Diagnosis of CHF mainly relies on imaging techniques, i.e. radiology and/or ultrasonography. 
Thoracic radiography is the gold standard for diagnosing pulmonary oedema (Ferasin and 
Defrancesco, 2015), however findings of pulmonary ultrasonography can also be suggestive 
(Boysen and Lisciandro, 2013). Pleural effusion, pericardial effusion and ascites may be 
appreciated on radiographs, however ultrasonography is a more sensitive and specific 
technique for the diagnosis of body cavity effusions.  
Routine haematology and biochemistry may give non-specific changes; azotaemia and 
electrolyte imbalance, particularly hypokalaemia, are common findings in CHF cats (Goutal et 
al., 2010). Concentrations of both circulating cardiac biomarkers, N-terminal pro-brain 
natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI), have been reported to be 
increased in CHF cats compared with asymptomatic CM patients (Connolly et al., 2008; Fox 
et al., 2011; Herndon et al., 2002; Hori et al., 2008), although elevated cTnI is not a consistent 
finding (Connolly et al., 2003).
 
1.2.3 Therapeutic Management 
Accurate recognition of CHF and the underlying cause is essential in CHF management (Côté, 
2017). A CHF therapeutic plan is targeting at opposing the neurohormornal response, reducing 
preload and afterload, improving cardiac output and cardiac function and reducing maladaptive 
cardiac remodelling. In acute CHF, minimising stress, oxygen supplement, intravenous loop 
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diuretic administration and draining body cavity centesis are common procedures required for 
providing immediate relief; in chronic CHF, the underlying cause should be identified and 
addressed if possible, loop and other diuretics, pimobendan, ACE inhibitors and spironolactone 
are drugs commonly used and the treatment plan is tailored for the individual (Côté, 2017).  
Furosemide is the most commonly used diuretic in treating both acute and chronic CHF. It is a 
loop diuretic and effective in reducing intravascular fluid accumulation (Ferasin and 
Defrancesco, 2015). The drawbacks of furosemide include a hypovolemic effect, impaired 
kidney function and a brake effect (diuretic tolerance) can develop during treatment (Côté, 
2017). Nevertheless, it is still the first line choice in managing feline CHF. Torasemide is also 
a loop diuretic, which is ten times more potent than furosemide. It is a relatively new diuretic 
in small animal cardiology and has attracted great attention recently. It has been reported to 
have less brake effect than furosemide (Uechi et al., 2003; Hori et al., 2007), and has been 
suggested as a replacement for furosemide in managing feline CHF, especially when tolerance 
develops (Côté, 2017). Additionally, torasemide appears to have additional beneficial effects, 
such as aldosterone receptor blockage and an anti-myocardial fibrosis effect (Yamato et al., 
2003; López et al., 2007). The thiazide diuretics, such as hydrochlorothiazide, and aldosterone 
blocker spironolactone may also be used as complementary diuretics to furosemide. 
Spironolactone is also thought to have anti-fibrotic effects in cardiac patients but this was not 
evident in one Maine Coon HCM study (MacDonald et al., 2008). The recent SEISICAT study 
suggest spironolactone is well tolerated and of a potential benefit for administration to cats in 
CHF (James et al., 2018). 
ACE inhibitors block the production of vasoconstrictor angiotensin II and increase the 
vasodilator bradykinin, which act to oppose RAAS activation (Davies et al., 2000). They are 
commonly used in feline chronic CHF management, although so far there is still a lack of clear 
evidence for their benefit in feline CHF (Ferasin and Defrancesco, 2015).  
Pimobendan is an inodilator that may improve vasodilation and cardiac contractility in CHF, 
but so far it is not licenced for use in cats. It has been reported that cats with CHF treated with 
pimobendan have increased survival compared with controls (Reina-Doreste et al., 2014).  
As arrhythmias are not uncommon in CHF cats, anti-arrhythmics may be considered for use in 
certain cases. Digoxin is recommended when there is concurrent poor LV systolic function and 
a fast supraventricular tachycardia. Beta-blockers, such as atenolol, are contraindicated in acute 
CHF, and in patients treated with beta-blocker prior to CHF development, the dose may need 
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to be adjusted after CHF develops based on individual status (Côté, 2017). Antithrombotic 
prophylaxis, such as clopidogrel, should be used in CHF cats with LA enlargement and/or 
spontaneous echo contrast, as they are at high risk of developing thromboembolism (Ferasin 
and Defrancesco, 2015).  
A well-known complication of CHF treatment, particularly with furosemide use, is renal 
dysfunction, with azotaemia and electrolyte disturbance commonly seen (Ferasin and 
Defrancesco, 2015). Routine monitoring of kidney function and electrolyte levels is 
recommended in treated CHF patients.
 
1.2.4 Survival and Prognosis 
In general, CHF is considered to have a poor long-term prognosis. Cats with CHF secondary 
to DCM, RCM and ARVC are reported to have worse survival compared with HCM (Atkins 
et al., 1992; Fox et al., 2000; Rush et al., 2002; Ferasin et al., 2003; Payne et al., 2010; Locatelli 
et al., 2018). The MST in HCM cats with CHF has been reported to be from 92-536 days 
(Atkins et al., 1992; Rush et al., 2002; Payne et al., 2010). In CHF secondary to DCM, ARVC 
and RCM, the MST has been reported to be 11 days (Ferasin et al., 2003), 30 days (Fox et al., 
2000) and 64-132 days (Ferasin et al., 2003; Locatelli et al., 2018). One exception is TMT 
induced CHF, which was shown to have a better prognosis than CHF due to HCM (Novo Matos 
et al., 2018).  
Prognostic factors have been investigated extensively in feline CHF associated with primary 
CM. The presence of LA enlargement based on echocardiography is the most consistent 
negative prognostic factor (Fox et al., 1995; Rush et al., 2002; Payne et al., 2010; Payne et al., 
2015a). Other reported risk factors in cats with CHF and CM include decreased LV fractional 
shortening (FS) (Petersen et al.,1993; Payne et al., 2015a), increased LV wall thickness (Fox 
et al., 1995), hypothermia at presentation (Goutal et al., 2010; Dickson et al., 2018), the 
presence of gallop sounds (Dickson et al., 2018), older age (Payne et al., 2015b; Rush et al., 
2002), the presence of arrhythmias (Payne et al., 2015b), the presence of spontaneous echo 
contrast/intra-cardiac thrombus (Payne et al., 2015a; Peck et al., 2016), LA dysfunction (Payne 
et al., 2015a), the need for thoracocentesis (Rush et al., 2002), right ventricular enlargement 
(Rush et al., 2002) and abnormal body weight (Finn et al., 2010). 
The CM cats (including those in CHF) with SAM and normal LA size are reported to have a 
better prognosis (Petersen et al., 1993; Fox et al., 1995; Rush et al., 2002; Payne et al., 2010; 
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Payne et al., 2015b). In Fox and colleagues’ study HOCM was associated with better survival 
in CHF cats (Fox et al., 1995), whereas in Payne and others’ study, SAM seemed only to be 
associated with asymptomatic status (Payne et al., 2010).
  
  
30 
 
1.3 Cardiovascular-renal Axis Disorder  
1.3.1 Definition of Cardiovascular-Renal Axis Disorder 
Cardiovascular-renal Axis Disorder (CvRD), or cardio-renal syndrome, is defined as acute or 
chronic cardiovascular and renal disease, with the dysfunction of one organ system 
subsequently inducing impaired function or injury to the other organ system (Pouchelon et al., 
2015). This disorder was first described in human medicine, with the term largely reserved for 
renal dysfunction in heart failure (Ronco et al., 2008). Since a CvRD consensus statement was 
released in 2015 (Pouchelon et al., 2015), it has gain more attention in veterinary medicine. 
CvRD in small animals has been divided into 3 classes; the CvRDH class is of particular interest 
in characterizing renal dysfunction caused by primary cardiovascular diseases. The potential 
underlying mechanisms of renal disorder in CvRDH include decreased cardiac output, reduced 
renal perfusion, neuroendocrine activation, reactive oxygen species production and passive 
renal congestion (Pouchelon et al., 2015). CvRDH can be further sub-classified into CvRDH 
(unstable disease), also called Acute Cardiorenal Syndrome, and CvRDH (stable disease), also 
called Chronic Cardiorenal Syndrome (Orvalho and Cowgill, 2017). Unstable CvRDH is 
associated with rapid cardiovascular decompensation such as acute heart failure, with acute 
renal injury occurring as a consequence of the event. Stable CvRDH results from chronic heart 
failure where the long term effect of inadequate cardiac output reduces renal perfusion and the 
activation of neurohormonal systems such as the SNS and RAAS eventually leads to 
progressive chronic renal disease (Ronco et al., 2008). Apart from the intrinsic interaction 
between the two organ systems, therapeutics agents used in CHF management, such as loop 
diuretics, also can exaggerate neurohormonal activation, reduce glomerular filtration rate (GFR) 
and worsen renal function (Francis et al., 1990; Lazzarini et al., 2012). Effective decongestion 
with diuretics in heart failure appears to be beneficial for patient survival, however, even at the 
cost of worsening renal function (Testani et al., 2010).   
In the 2015 CvRD consensus statement, the importance of addressing the renal issue at the 
same time as CHF management achieved strong agreement between veterinary cardiologists 
and nephrologists (Pouchelon et al., 2015). The endeavor should be to focus on maximally 
preserving both cardiac and renal function, which will mutually benefit the two organ systems 
and eventually improve overall clinical outcomes. 
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1.3.2 Biomarkers for CvRD Detection 
The detection of CvRD relies on cardiac and renal specific biomarkers in conjunction with 
diagnostic imaging tests such as ultrasonography (Orvalho and Cowgill, 2017). A cardiorenal 
biomarker panel for assessing cardiorenal syndrome has been proposed (Pouchelon et al., 2015; 
Orvalho and Cowgill, 2017). These biomarkers include renal function markers, novel kidney 
injury or stress markers and cardiac biomarkers (Orvalho and Cowgill, 2017). A combination 
of renal and cardiac biomarkers could be a substitute for current clinical diagnostics. Potentially 
they can provide more accurate information on both cardiac and renal function in a ‘timely 
manner’, serve as disease monitors and guide the clinician in making decisions on a therapeutic 
plan (Orvalho and Cowgill, 2017).  
Currently in veterinary medicine the most well established renal functional marker is creatinine. 
It is an end-product of muscle metabolism, which has been found to be correlated with GFR 
and it is increased in renal disease when there is 75% kidney functional loss (Finco et al., 1995; 
Relford et al., 2016). Traditionally, the serum creatinine concentration was used for kidney 
disease staging, an increase in creatinine of more than 0.3mg/dl within 48 hours was considered 
to be indicative of acute kidney injury (AKI) (http://www.iris-kidney.com/pdf/4_ldc-revised-
grading-of-acute-kidney-injury.pdf). According to the International Renal Interest Society 
(IRIS) guidelines, the absolute value of creatinine in non-azotaemic renal disease is defined as 
<140 μmol/l, and in mild AKI as 140-220 μmol/l. These values largely overlap with the normal 
reference range, which suggests that serum creatinine is not sensitive for detecting early AKI 
(Pouchelon et al., 2015). Moreover, the increase in creatinine concentration is largely not 
specific for renal disease; its expression is affected by lean muscle mass and potentially 
affected by a number of other factors including age, diet, body weight, medication usage and 
disease conditions associated with dehydration (Baxmann et al., 2008; Miyagawa et al., 2010; 
Watson et al., 1981; Yerramilli et al., 2016).  
Considering that early recognition of AKI is essential for taking prompt action to protect the 
kidney, more sensitive renal biomarkers are needed for early diagnosis (Ronco et al., 2008). 
For this purpose, novel renal biomarkers have been identified recently in veterinary medicine, 
including symmetric dimethylarginine (SDMA), neutrophil gelatinase-associated lipocalin 
(NGAL), inosine, clusterin, cystatin B, kidney injury molecule-1, N-acetyl-beta-
glucosaminidase (NAG) and retinol binding protein (Bland et al., 2014; Chacar et al., 2017; 
Lapointe et al., 2008; Orvalho and Cowgill, 2017; De Loor et al., 2013; Segev et al., 2013; 
Yerramilli et al., 2016). 
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SDMA has attracted attention as an alternative renal functional biomarker to creatinine in small 
animal medicine (Kielstein et al., 2006; Relford et al., 2016). It is a form of by-product of 
amino acid arginine methylation (Kakimoto and Akazawa, 1970), which is primarily 
eliminated by the kidney (McDermmott, 1976). In cats, it has been shown SDMA has a strong 
inverse correlation with GFR, therefore it can indirectly reflect renal function (Braff et al., 
2014). Previous research in cats showed SDMA started to increase when GRF decreased by 
25%, and its response to kidney disease was on average 17 months earlier than creatinine (Hall 
et al., 2014b). Unlike creatinine, SDMA is not affected by body lean mass, and thus may be 
more accurate as a renal marker particularly in cachexia or geriatric patients with muscle loss 
(Hall et al., 2014c). In the 2016 modified IRIS staging of chronic kidney disease (CKD) 
statement, SDMA was recommended to be used in assisting the previous creatinine based 
staging system. i.e. persistent increase in SDMA more than 14 ug/dl should be considered 
significant despite a creatinine value still in the normal range.  
The value of using SDMA to detect early renal impairment in cats has been investigated in a 
few studies. A good example is a recent study investigating SDMA in feline hyperthyroidism 
before and after I131 therapy (Peterson et al., 2018). Initially, all cats prior to I131 treatment 
were non-azotaemic and after treatment azotaemia was revealed in 16% cats and a third of 
those cats had high SDMA prior to I131 treatment, which suggested SDMA has the ability to 
detect CKD masked by feline hyperthyroidism. They also assessed the diagnostic value of 
SDMA for masked CKD, showing that SDMA had a sensitivity of 33% and a specificity of 
97.7%. Another study has suggested that SDMA is a superior marker for early renal disease 
detection compared with conventional creatinine and urea (Hall et al., 2016). They compared 
6 monthly changes in serum SDMA and creatinine in a population of 80 geriatric cats fed with 
different types of diet; 28.8% IRIS stage I CKD was detected by elevated SDMA (>14 μg/dl) 
but not by creatinine, which confirms SDMA is a more sensitive marker for detecting early 
renal insufficiency. 
In general, the specificity of SDMA as a renal marker is superior to creatinine, although its 
expression was found to be higher in older cats (Hall et al., 2014c). Apart from primary renal 
disease, it may also increase in other systemic conditions associated with reduced GFR and 
secondary renal dysfunction, such as feline hyperthyroidism, general anaesthesia and neoplasia 
(Peterson et al., 2018; Befu et al., 2018; Coyne et al., 2018).  
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In the past, SDMA was considered as a non-functional molecule, purely serving as a renal 
functional tracer. More recent human studies suggested SDMA may also act as a pro-
inflammatory factor in chronic renal disease (Schepers et al., 2011). In vitro experiments 
showed it enhanced intracellular expression of inflammatory cytokines tumour necrosis factor-
alpha (TNF-α) and interleukin-6 (IL-6) in monocytes. The same study also established an 
inflammatory analysis model in clinical CKD patients, in which SDMA was found closely 
correlated with conventional inflammatory markers (Schepers et al., 2011). The isomer of 
SDMA, asymmetric dimethylarginine (ADMA), has been recognized for decades as an 
inhibitor of nitric oxide synthase (NOS) and is involved in endothelial dysfunction (Vallance 
et al., 1992). Traditionally SDMA was not thought to be involved in the same pathological 
pathways, but newer evidence has shown it may be a mediator in endothelial dysfunction by 
competing with NOS and stimulating reactive oxygen species production when there is 
vascular injury (Closs et al., 1997; Kielstein et al., 2006; Schepers et al., 2011). Multiple studies 
have consistently demonstrated SDMA has an independent risk prediction value in 
cardiovascular disease (Schlesinger et al., 2016), which suggest an intrinsic link between 
SDMA and cardiovascular disorders.  
The second essential part of a CvRD biomarker panel is cardiac biomarkers such as NT-
proBNP and cTnI. The properties of the cardiac biomarkers will be discussed in detail in 
Section 1.5. A combination of renal and cardiac biomarkers would potentially allow sensitive 
detection and monitoring of CvRD and would be valuable for future clinical practice.
 
1.3.3 Role of CvRD in CHF  
In humans, renal dysfunction is a common condition in heart failure and it has been found as 
an independent poor prognostic factor for heart failure survival (Hillege et al., 2000; Hillege et 
al., 2006; McClellan et al., 2002). In a veterinary 3-month survival analysis study, it was shown 
that dogs and cats that developed azotaemic AKI had at least a 3 times higher risk of mortality 
(Harison et al., 2012). Although CvRD is a relatively new concept in small animal medicine, 
the high prevalence of azotaemia in CHF has been well recognized (Gouni et al., 2008; Goutal 
et al., 2010; Nicolle et al., 2007; Yu et al., 2016; Martinelli et al., 2016). In dogs in CHF due 
to degenerative mitral valve disease (DMVD), the prevalence of azotaemia was reported as 
being 32%-71% in different studies, with a consistently higher incidence of azotaemia observed 
in more advanced heart failure in all of these studies (Nicolle et al., 2007; Yu et al., 2016; 
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Martinelli et al., 2016). A preliminary investigation of CvRD in DMVD dogs showed that 
chronic renal disease severity was positively correlated with the severity of CHF. The treated 
CHF dogs had a significantly higher incidence of CKD compared with untreated dogs. 
Moreover, the DMVD dogs that developed CvRD had a significantly shorter survival time 
compared with those without CvRD (Martinelli et al., 2016). In feline patients, to the author’s 
knowledge, CvRD has not yet been reported. One retrospective study reported that azotaemia 
occurred in 58.8% of feline HCM cases; interestingly there was no significance difference 
between CHF cases and non-CHF cases in creatinine and urea levels (Gouni et al., 2008). 
Another study looked at azotaemic parameters in cats developing acute CHF during 
hospitalization and found that increased creatinine occurred in 53% of the CHF cats (Goutal et 
al., 2010). The high prevalence of azotaemia in heart failure is thought to be a reflection of 
CvRD, whether it is a result of intrinsic organ interactions or of iatrogenic origin (e.g. loop 
diuretics), it should not be neglected (Orvalho and Cowgill, 2017).  
SDMA has been recently investigated as a CvRD marker in advanced stage CHF in dogs, 
finding that a progressively elevated SDMA level was correlated with increased heart failure 
severity (Choi et al., 2017). Renal injury marker Cystatin-C demonstrated similar changes to 
SDMA in the same study, and both markers were well correlated with the traditional renal 
parameters creatinine and urea.  
Early detection and careful management of CvRD will influence the outcome of CHF. For 
example, worsening renal function and excessive use of diuretics in acute CHF management 
may lead to diuretic resistance, which is detrimental to both cardiac and renal function (Liang 
et al., 2008). Therefore, from a clinical point of view, CvRD should be detected and addressed 
as soon as possible in CHF patients.
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1.4 Inflammatory Responses and Acute Phase Proteins 
1.4.1 Overview of Inflammation and Heart failure 
The involvement of inflammation in heart failure has been recognized, however the complex 
underlying mechanism is yet to be fully understood. Whether inflammation is a cause or 
consequence of heart failure has been extensively explored; the most prevailing understanding 
suggested that inflammation and heart failure reciprocally affect each other, namely forming a 
vicious cycle (Van Linthout and Tschope, 2017). Inflammation can trigger or exaggerate heart 
failure in a number of ways, through either the systemic circulation or local organ effects. 
Documented mechanisms include triggering cardiac cellular apoptosis and maladaptive 
hypertrophy, endothelial dysfunction, abnormal ECM remodelling and endothelial 
mesenchymal transition, eventually leading to macroscopic cardiac remodelling and 
dysfunction. In heart failure, induced local or systemic sterile inflammation can also occur as 
a response to cardiac cytokine release in the decompensated heart (Dick and Epelman, 2016; 
Van Linthout and Tschope, 2017). To investigate the role of inflammation in heart failure, a 
biomarker-based approach shows its merits; it potentially can help to understand the aetiology 
and pathogenesis of heart failure and may identify therapeutic targets and aid in disease 
surveillance and prognosis (Bozkurt et al., 2010). Currently the main inflammatory mediators 
investigated in heart failure include pro-inflammatory cytokines and acute phase proteins 
(Bozkurt et al., 2010; Braunwald, 2008; Mavropoulou et al., 2016). 
 
1.4.2 Acute Phase Proteins 
The acute phase response has been described as an innate immune response to stimuli occurring 
in trauma, infection, stress, neoplasia and inflammation processes (Cray et al., 2009). Acute 
phase proteins (APPs) are important biological reactants released during the acute phase 
response. So far more than 200 APPs have been reported, but their full functions are still under 
investigation (Cray et al., 2009). The APPs are predominantly produced by hepatocytes, 
although other organs such as adipose tissue have also been found to have the ability to produce 
APPs (Ahmed et al., 2012). Depending on the response to stimulation, the APPs are classified 
into negative and positive groups. The former decrease during the inflammatory response, and 
the latter (positive APPs) showing an increase in expression during inflammation (Ceron et al., 
2005). Common negative APPs in humans and in dogs and cats include albumin and transferrin; 
positive APPs include C-reactive protein (CRP), serum amyloid A (SAA), alpha-1-acid 
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glycoprotein (AGP), haptoglobin (Hp), fibrinogen, ceruloplasmin and leucine-rich alpha-2-
glycoprotein1 (LRG1) (Ceron et al., 2005; Shirai et al., 2009). Depending on their differential 
rate and pattern of response to stimuli, the positive APPs can be further classified into three 
groups: major, moderate and minor (Eckersall and Bell, 2010). Major APPs have the fastest 
response rate, usually increasing within the first 48 hours to reach a peak, then declining rapidly. 
The levels of increased expression can be 10-100 fold compared to normal. Moderate APPs 
have slower response rates and less marked rises (5-10 fold) compared with major APPs, 
usually peaking after 2-3 days before starting to decline. Minor APPs have the slowest response 
and degradation rates and also the lowest rise in concentration (Eckersall and Bell, 2010). There 
are variations between different species in APP expression. For example, in dogs the most 
important major APP is considered to be CRP, while in cats, CRP seems to be less useful 
(Kajikawa et al., 1999). The most well established major APPs in cats are SAA and AGP, and 
Hp is the most common minor feline APP (Ceron et al., 2005). 
It should be noted that APPs are highly sensitive biomarkers and they lack specificity, as they 
can be involved in multiple disease processes. Therefore the interpretation of APPs should be 
done with caution, especially when trying to clarify their roles in specific diseases. An editorial 
review was published in 2008 in which guidelines for APPs interpretation were proposed in 
small animal medicine; this provides valuable guidance for clinical application as well as for 
APP related scientific study design (Ceron et al., 2008). According to the guidelines, species 
specific tests should be used whenever possible and an APP profile should include at least one 
major and one moderate APP. Although it is essential to obtain baseline data on APPs in 
associated disease processes, in order to investigate disease pathophysiology, investigations of 
APP changes in a temporal manner would provide information for disease monitoring and 
prognosis (Ceron et al., 2008; Eckersall and Schmidt, 2014). Additionally, it has been 
suggested that an increase in APPs in a clinical healthy animal may potentially indicate the 
presence of subclinical disease (Ceron et al., 2008).  
Although the APPs were discovered a long time ago, they only become popular in veterinary 
medicine in last two decades. Most APP studies in dogs and cats focus mainly on infectious 
conditions, traumatic/inflammatory events and neoplasia (Kajikawa et al., 1999; Eckersall and 
Schmidt, 2014). In feline medicine, it is known that AGP has good diagnostic value in feline 
infectious peritonitis (FIP) (Paltrinieri et al., 2007; Hazuchova et al., 2017) and SAA can be a 
prognostic factor in sick or hospitalized cats with various disease conditions (Kajikawa et al., 
1999; Kann et al., 2012; Tamamoto et al., 2013). The role of APPs in specific systemic 
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inflammatory diseases, such as pancreatitis and anaemia secondary to inflammation and 
chronic renal disease, has also been investigated (Tamamoto et al., 2009; Ottenjann et al., 2006; 
Javard et al., 2017). Currently, several APPs are available for assessing and monitoring 
infectious or inflammatory disease status. Common APP profiles in dogs are CRP/Hp and in 
cats are SAA/AGP/Hp (Ceron et al., 2008). Apart from these, a huge knowledge gap exists 
regarding other APPs in small animal patients.
 
1.4.3 APPs in Cardiovascular Diseases 
APPs have been studied in human cardiovascular disease research. A good review article from 
1999 discussed the role of CRP in cardiovascular disease; by then the circulating CRP level 
was already known as an independent risk factor for cardiovascular events (Lagrand et al., 
1999). Over the past 20 years more APPs were identified as having connections with 
cardiovascular diseases, and their interactions with the circulatory system seem to go beyond 
straightforward inflammation (Ahmed et al., 2012; Kumagai et al., 2016; Watson et al., 2011). 
For example, LRG1 was found to protect against adverse myocardial and vascular remodelling 
in heart disease, potentially by interfering with the transforming growth factor-beta (TGF-β) 
pathway (Song and Wang, 2015; Kumagai et al., 2016). Ceruloplasmin is a metalloprotein that 
binds most of the copper in plasma and has documented functions including iron detoxification 
and an association with oxidative stress (Ceron et al., 2005; Cao and Hill, 2014). Both LRG1 
and ceruloplasmin were found to be increased in heart failure in humans (Watson et al., 2011; 
Hammadah et al., 2014; Cabassi et al., 2014; Dadu et al., 2013). SAA, AGP, Hp and 
procalcitonin (PCT) are other examples of APPs that have been found to be associated with 
cardiovascular disease (Singh-Manoux et al., 2017; Johnson et al., 2004; Fischer et al., 2014; 
Holme et al., 2009; Suleiman et al., 2005; Canbay et al., 2015; Mockel et al., 2017) and to date, 
more investigations are still needed to characterize their full functions. 
Regarding APPs in small animal cardiovascular diseases, published data were mainly related 
to dog DMVD. CRP is the most widely investigated APP in canine mitral valve disease, and 
several studies have reported CRP to be increased in canine CHF and that its elevation 
amplitude was correlated with CHF severity (Cunningham et al., 2012; Domanjko Petric et al., 
2018; Polizopoulou et al., 2015; Reimann et al., 2016). Although CRP does not differentiate 
DMVD groups at different severities (Ljungvall et al., 2010; Rush et al., 2006), consistently 
serum CRP appears to positively correlate with cTnI in DMVD dogs (Polizopoulou et al., 2015; 
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Ljungvall et al., 2010). Moreover, in symptomatic DMVD dogs, CRP was also found to 
associate with echocardiographic changes such as increased left atrium to aortic root ratio 
(LA/Ao) and LV diameter during diastole, increased mitral valve inflow E wave velocity and 
decreased LV ejection fraction (Reimann et al., 2016; Domanjko Petric et al., 2018). Other 
APPs were investigated in canine DMVD, including Hp and ceruloplasmin, with Hp found to 
have significantly higher expression in the severe disease group compared with asymptomatic 
patients (Polizopoulou et al., 2015). 
There is less information regarding the involvement of APPs in feline cardiovascular disease. 
A very recent scientific report showed SAA to be increased in asymptomatic HCM cats with 
global LV hypertrophy, which suggested an involvement of SAA in feline CM (Van Hoek et 
al., 2018a). In one FIP focused study, CHF cats that developed body cavity effusions were 
evaluated for SAA, Hp and AGP expression (Hazuchova et al., 2017). Compared with FIP, the 
CHF cats had significantly lower SAA, Hp and AGP levels, however no healthy control cats 
were used in the study for comparison.    
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1.5 Biomarkers in Cardiology 
The original definition of a biomarker was established in 2001: ‘a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention’ (Atkinson et al., 2001). It 
has been proposed that biomarkers could contribute to both research and clinical medicine. 
From upstream in vitro and in vivo studies to downstream clinical application, they may serve 
as valuable tools in understanding disease pathogenesis, aiding disease diagnosis and staging, 
indicating disease prognosis and monitoring patients’ response to therapeutics (Atkinson et al., 
2001). 
Given the above merits, biomarkers have emerged in the past decade in cardiovascular 
medicine. Extensive research work has been carried out on developing novel biomarkers for 
cardiovascular diseases. A rationale for assessing novel clinical cardiovascular biomarkers was 
summarized in one review. In general, three criteria were proposed: (1) whether the biomarker 
is measurable; a biomarker test should be accurate, reproducible and readily accessible with 
reasonable cost; (2) whether the biomarker provides additional information supplementary to 
existing clinical tests; (3) whether the biomarker can help to make clinical decisions in patient 
management, such as guiding a therapeutic plan and risk assessment etc. (Morrow and De 
Lemos, 2007). 
In humans, biomarkers in heart failure have been developed in relation to inflammation, 
oxidative stress, ECM remodelling, neurohormonal regulation, myocardial injury and fibrosis, 
myocardial stress, CvRD and other pathophysiological pathways (Braunwald, 2008; Senthong 
et al., 2017). Genomic, metabolomic and proteomic techniques were also implemented recently 
to explore novel biomarkers for heart failure. 
In small animal cardiology, current clinical biomarkers are restricted to NT-proBNP and cTnI. 
Both biomarkers are reasonably well established in cats and they have been shown to have 
value in feline cardiac disease management (Borgeat et al., 2015a). 
NT-proBNP is an inactive form of cleaved product from the prohormone brain natriuretic 
peptide (Harris et al., 2017b). Brain natriuretic peptide (BNP) is secreted by atrial and 
ventricular myocytes in response to myocardial stretch, its main function being to regulate 
plasma volume and promote natriuresis when there is volume or pressure overload in the 
ventricle, which can counteract RAAS activation (Volpe et al., 2016). NT-proBNP has a longer 
half-life than BNP, thus it is more stable for assessment as a biomarker of myocardial stress 
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(Braunwald, 2008). In previous feline CM studies, NT-proBNP has demonstrated reasonably 
good ability consistently in differentiating healthy, asymptomatic HCM from CHF cats 
(Connolly et al., 2008; Wess et al., 2009; Fox et al., 2011). With a cut off at 100 pmol/l, the 
reported sensitivity and specificity of detecting sub-clinical HCM was 94% and 81% 
respectively (Wess et al., 2009); the sensitivity and specificity of detecting asymptomatic feline 
cardiac disease (primary CM) was 84.6% and 100% respectively (Harris et al., 2017a). It is 
also a valuable tool in differentiating cardiogenic respiratory distress from primary respiratory 
disease in cats (Connolly et al., 2009; Fox et al., 2009; Hassdenteufel et al., 2013). One recent 
study investigated NT-proBNP in CHF cats with short term follow up, and it has shown that 
greater reduction of NT-proBNP in response to hospitalization may be a positive indicator for 
survival in cats (Pierce et al., 2017). The prognostic potential of NT-proBNP in feline heart 
disease has been noticed for a long time (Borgeat et al., 2014b), but so far there is no evidence 
supporting its use as an independent risk predictor. A partial reason for this may be the high 
biological variability of NT-proBNP in individual cats, which makes it challenging to interpret 
changes in a temporal manner (Harris et al., 2017b). Prohormone atrial natriuretic peptide 
(proANP) is another myocardial stress marker which is similar to NT-proBNP. Increased 
concentrations seem to correlate with severity of HCM especially when the disease is in a more 
advanced stage (Zimmering et al., 2009; Parzeniecka-Jaworska et al., 2016). In general, it has 
not shown superior characteristics to NT-proBNP in diagnosing and staging feline CM 
(Connolly et al., 2008).  
cTnI and cardiac troponin T (cTnT) are biomarkers of myocardial injury, with cTnI currently 
more widely used in the feline field (Borgeat et al., 2015a). Similar to NT-proBNP, cTnI also 
has some value in detecting asymptomatic CM and differentiating cardiogenic respiratory signs, 
but it has been considered less useful than NT-proBNP in these two aspects (Borgeat et al., 
2015a). In a previous study, an increased concentration of cTnI was found to be associated with 
a risk of death in feline HCM, but this did not stay in the final survival analysis model, while 
cTnT turned out to be a significant prognosticator (Langhorn et al., 2014).  
Both NT-proBNP and cTnI are known to increase in other systemic disease conditions. For 
example, NT-proBNP and cTnI have been found to increase in feline hyperthyroidism 
(Sangster et al., 2014); an increased concentration of NT-proBNP has been associated with 
systemic hypertension in CKD cats (Lalor et al., 2009); increased concentrations of cTnI were 
reported in anaemia (Lalor et al., 2014). Additionally, since both NT-proBNP and cTnI are 
partially eliminated by the kidneys, it has been proposed that renal function should be taken 
  
41 
 
into account when interpreting these two biomarkers, especially if a patient has concurrent 
cardiac and renal disease (Orvalho and Cowgill, 2017). 
Recently, other potential cardiac biomarkers have been investigated in small animal medicine, 
particularly in association with CM and CHF. These include inflammatory cytokines (Reimann 
et al., 2016; Cunningham et al., 2012; Fonfara et al., 2012), ECM remodelling markers (Borgeat 
et al., 2015b; Fonfara et al., 2013; Aupplerle et al., 2011), markers of CvRD (Choi et al., 2017; 
Orvalho and Cowgill, 2017), metabolic markers (Fonfara et al., 2017), haemostatic factors 
(Tablin et al., 2014; Tarnow et al., 2007) and more advanced global discovery approaches 
including genomics (Lu et al., 2015; Oyama and Chittur, 2006) and proteomics (Locatelli et 
al., 2017).  
There is a great need to develop novel biomarkers for disease diagnosis, management and 
prognosis in veterinary cardiology. A multiple biomarker-based scoring approach for risk 
stratification has been advocated in human medicine in the past 10 years, and the evaluation 
outcome looks very promising (Senthong et al., 2017; Braunwald, 2008). This could also be a 
future direction in veterinary medicine - a new era of multiple biomarker-based medicine. 
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1.6 Aims, Scope and Hypotheses 
Aims 
The aims were to evaluate whether CvRD and an inflammatory response occur in feline CHF 
due to primary CM, and to identify novel biomarkers for feline CHF and CM.  
Scope 
The study population contained CM cats diagnosed at the Cardiology Service of the University 
of Glasgow from 2014 to 2017, the majority of enrolment being done from 2016 to 2017. 
Serum samples were collected from cats and stored for batch analysis, and clinical records of 
the CM cats were collated. Serum biomarker assays were performed by collaborating IDEXX 
reference laboratories and Life Diagnostics Inc., USA. A panel of markers for CvRD and a 
panel of APPs were assessed respectively in CM cats with CHF, CM cats without clinical signs 
and healthy controls.  
A preliminary longitudinal study was carried out in CHF cats, when biomarker changes were 
tracked 12 months for each individual. 
Hypotheses 
1. CvRD occurs in feline CHF due to primary CM; NT-proBNP and renal function 
markers are associated with survival in CHF cats. 
2. Inflammatory responses occur in feline CHF due to primary CM; selected APPs are 
associated with survival in CHF cats. 
3. By measuring biomarkers at a series of planned time points, optimal time points for 
predicting disease prognosis may be determined in CHF cats. 
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Chapter 2: Materials and Methods 
2.1 Summary of Study Design  
The object of this study was to investigate whether CvRD and inflammatory responses occur 
in feline CHF secondary to CM. Two panels of serum protein markers were assessed, and the 
aim was also to identify whether these markers could be used as novel biomarkers for CHF 
management and prognosis.  
The study populations included three cat groups: cats diagnosed with CHF due to primary CM 
(the CHF group), cats diagnosed with asymptomatic CM (the asymptomatic group) and healthy 
controls. Inclusion and exclusion criteria, definitions of terms and classifications used in the 
study were established during the study design.  
There were two parts to this study (Figure 2.1): Part 1-baseline study. The intrinsic differences 
in the expression of the biomarkers were compared in the three cat groups. Additionally, 
clinical parameters, correlation of biomarkers and clinical variables were also assessed, and a 
survival analysis was performed in CHF cats. Part 2-longitudinal study. This was carried out 
in the CHF group. After initial sample collection, CHF cats which were enrolled during this 
time period had follow-up blood sampling at subsequent revisits. Serial biomarker levels were 
measured in follow-up samples and the trends of biomarker changes were assessed over time. 
Clinical data and blood samples were collected from candidate CM cats in the Cardiology 
Service of the Small Animal Hospital, University of Glasgow. Serum samples were stored for 
batched biomarker tests. Healthy cat serum samples obtained from a commercial source were 
used as controls. 
CvRD biomarker analysis was performed in IDEXX reference laboratories; the profile included 
NT-proBNP, SDMA and creatinine. Inflammatory response was assessed by analysing a panel 
of APPs including AGP, CRP, Hp, LRG1, SAA, PCT and ceruloplasmin. The APP work was 
performed in a collaborating laboratory in the USA.  
After data collection, statistical analysis was performed. One-way analysis of variance 
(ANOVA) and Student’s T test were used to compare quantitative data between groups. Chi-
square and Fisher exact tests were used to compare categorical data between groups. 
Spearman’s rho test was used to assess correlations among variables. Cox proportional hazards 
models were used for survival analysis in the CHF cats.    
  
  
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Illustration of cat enrolment for the biomarker baseline and longitudinal study. 
Originally 41 CM cats entered in the study; after initial exclusion, 25 CHF and 12 
asymptomatic cats were enrolled and used for baseline characteristics analysis. 
 
 
 
 
  
  
45 
 
2.2 Study Population  
2.2.1 CM Cats 
From January 2014 to August 2017, 41 cats diagnosed with CMs were recruited to the study 
in the Cardiology Service of the Small Animal Hospital at the University of Glasgow with full 
owner consent. Among the candidate cats, 27 cats were in CHF and 14 cats had asymptomatic 
CM. The following inclusion and exclusion criteria were used for candidate selection: 
Inclusion criteria 
 Any type of primary CM diagnosed by echocardiography including HCM, HOCM, 
DCM, UCM, RCM and ARVC. 
Exclusion criteria 
 CM secondary to hyperthyroidism or hypertension. For hyperthyroidism, cats older 
than 6 years were screened based on clinical records. In cats older than 6 years old 
without thyroid function test results, serum thyroxine (T4) was tested retrospectively 
before a decision on final enrolment was made. Cats less than 6 years of age were 
exempted from thyroid function testing, as they were unlikely to be affected. For 
hypertension screening, a consistent reading of systolic blood pressure (BP) ≥ 180 
mmHg or ≥ 160 mmHg with retinal changes were considered as systemic hypertension 
(Payne et al., 2013). 
 Primary CKD history-IRIS stage ≥ II (http://www.iris-kidney.com/pdf/3_staging-of-
ckd.pdf) (Table 2.1) at the time CM was first diagnosed.  
 A diagnosis of other conditions that have been reported to trigger an acute phase 
reaction, including any active infectious diseases, recent inflammatory events (surgery 
or trauma) or certain systemic diseases (pancreatitis, neoplasia and anaemia secondary 
to chronic inflammatory disease). 
Four cats were further excluded from the study for the following reasons: in the CHF group, 
one cat was later found to have hyperthyroidism and for another cat, it was not possible to 
collect sufficient blood to run the planned biomarker tests; in the asymptomatic CM group, one 
cat had echo data missing, and another cat died due to the sudden onset of ATE, but clinical 
CHF development could not be ruled out. Finally, 37 CM cats (25 CHF cats and 12 
asymptomatic CM) were enrolled in the study.  
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Table 2.1. Staging of feline CKD based on blood creatinine concentration  
Stage Blood Creatinine (μmol/l) Comments 
At risk < 140 History suggests the animal is at risk of 
developing CKD in the future due to various 
factors. 
1 < 140 Non-azotaemic. Some renal abnormality is 
present e.g. inadequate concentrating ability, 
abnormal renal palpation or imaging 
findings. 
2 140-250 Mild azotaemia. Clinical signs usually mild 
or absent. 
3 251-440 Moderate renal azotaemia. Many extra renal 
clinical signs may be present. 
4 >440 Increased risk of systemic clinical signs and 
uremic crises 
 
2.2.2 Healthy Control Cats  
Commercial serum samples (Biobest, UK) from 20 clinically healthy cats were used as controls, 
with age and sex information available. Four cats were older than 6 years, and a retrospective 
T4 test ruled out hyperthyroidism in these cats. As echocardiography data was not available, 
all the healthy control cats were screened using NT-proBNP to eliminate occult heart disease. 
One cat had an NT-proBNP value of 29 pmol/l, but the NT-proBNP concentrations for the 
other 19 cats were below the lowest level of the reference range (<24 pmol/l). IDEXX reference 
laboratory’s recommended cut off to differentiate healthy and asymptomatic cardiac diseased 
cats is 100 pmol/l (Cardiopet proBNP) (Wess et al., 2009; Harris et al., 2017a). Therefore, these 
cats were believed to be free from occult CM. 
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2.3 Diagnoses of CM and CHF 
2.3.1 CM Diagnosis and Classification 
CMs were diagnosed with echocardiography performed by a European College of Veterinary 
Internal Medicine (ECVIM) Board-certified Cardiologist, or ECVIM residents in Cardiology 
or a Cardiology Certificate trainee working under the supervision of an ECVIM Board-certified 
Cardiologist. For cats that had multiple echocardiographic examinations performed, the results 
obtained closest to the time of 1st blood sample collection were used for the CM diagnosis and 
echo variable analysis. Based on 2D, M-mode and Doppler echocardiography parameters, 
candidate cats were diagnosed with one of the following conditions at study entry: HCM 
(including HOCM), DCM, UCM, RCM or ARVC. Details of the echocardiography diagnostic 
criteria are listed in Table 2.2. Final echo measurements and the CM classification for each 
individual cat were approved by an ECVIM Board-certified cardiologist.    
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Table 2.2. Classification and diagnostic criteria for feline CM 
CM Classification Diagnostic Criteria Based on Echocardiography 
HCM Left ventricular hypertrophy was defined as an end-diastolic 
maximal thickness of the left ventricular free wall (LVFWd) or 
interventricular septum (IVSd) of ≥  6 mm (Fox et al., 1995); 
and/or evidence of focal hypertrophy in the left ventricle (Ferasin, 
2009). HOCM was included in this category in the current study, 
which was characterized by presence of LVOTO. 
RCM Characterized by marked bi-atrial enlargement without significant 
myocardial hypertrophy, normal or mildly reduced myocardial 
systolic function, and diastolic dysfunction i.e. a restrictive left 
ventricular filling pattern confirmed with Doppler 
echocardiography (Fox et al., 2014).  
DCM Characterized by dilation of the left ventricular lumen and 
decreased myocardial function. In the current study the following 
cut-offs were used: left ventricular internal diameter end diastole 
(LVIDd) > 18 mm, left ventricular internal diameter end systole 
(LVIDs) > 12 mm, LV FS < 30%. Normal ranges vary considerably 
in the literature (Côté et al., 2011c; Pion et al., 1992; Ferasin, 2009). 
ARVC  Marked right side cardiac chamber enlargement particularly right 
ventricular dilation with thinning of the myocardium, right atrial 
dilation and an apical ventricular aneurism may also be present. 
Mild tricuspid valve regurgitation may be seen (Côté et al., 2011e; 
Fox et al., 2000). 
UCM Myocardial abnormalities that do not readily fit into any of the 
classifications defined above (Ferasin et al., 2003). 
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2.3.2 CHF Diagnosis and Classification  
CHF was diagnosed based on clinical history, presentation and evidence on thoracic 
radiographs and/or on ultrasonography. Presentations of CHF include pulmonary oedema, 
pleural effusion, pericardial effusion and ascites. 
The cardiac decompensation status of CM cats was staged based on the ISACHC classifications 
(Table 2.3) (Fox et al., 1999). CHF group in the current study refers to ‘clinical CHF’, which 
contained cats belonging to ISACHC Class II, IIIa or Class IIIb; the asymptomatic group 
contained cats belong to ISACHC Class Ia or Ib. 
Table 2.3. ISACHC classification  
Class Criteria  
I asymptomatic patient Ia-heart disease present, no clinical signs, no 
evidence of cardiac remodelling; 
Ib-heart disease present, no clinical signs, 
evidence of cardiac remodelling is present. 
II mild to moderate heart failure Clinical signs evident at rest or with mild exertion, 
adversely affected quality of life, home treatment 
indicated. 
III advanced heart failure IIIa-heart disease with clinical signs of advanced 
CHF at rest, home treatment indicated. 
IIIb-heart disease with clinical signs of advanced 
CHF at rest, hospitalization required for 
management.   
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2.4 Clinical Record Collection  
Relevant clinical records of CM cats were documented during the study period (i.e. by 
November 2017). History records were checked through hospital archives or the electronic 
medical records system (Excelicare, AxSys Technology, UK) installed in the Small Animal 
Hospital. The following details were recorded for candidate cats at entry to the study: animal 
name, case number, date of birth, sex, breed, date of initial diagnosis (Table 2.4), age at initial 
diagnosis, CM diagnosis, CHF diagnosis, serum T4 level, systolic BP and comorbidities. Echo 
variables (Table 2.5) which have been reported to be associated with severity and prognosis of 
feline CM were recorded, including LA diameter (mm), LA/Ao ratio, LVFWd (mm), IVSd 
(mm), LV FS %, presence of spontaneous echo contrast (‘smoke’) or intra-cardiac thrombus 
(Payne et al., 2013; Payne et al., 2015a). 
The following clinical information was recorded at the time of each blood sampling: sampling 
date, age at sampling, body weight, heart rhythm during auscultation, presence of gallop sounds, 
heart murmur, pulse deficit, heart rate, respiratory rate, ECG, CHF severity based on ISACHC 
classification (Table 2.4), cTnI, haematocrit and cardiac medication status.  
Prior to final statistical analysis in November 2017, CM cat survival information was collected. 
The information was mainly collected through the Excelicare system, with the rest of the 
information clarified by contacting the relevant referring veterinary practice or client. The 
following information was recorded for survival analysis: survival status (alive or dead), date 
of death (if applicable), cause of mortality (if applicable) and date of last contact (if applicable) 
(Table 2.4). 
Additionally, the following information was collected in the CHF cats:  overall CHF stability 
during the study, times of thoracocentesis, total days in the intensive care unit (ICU) during the 
study, concurrent cardiac arrhythmia, concurrent thrombotic/pro-thrombotic events (i.e. 
spontaneous echo contrast, intra-cardiac thrombus observed on echocardiography and ATE) 
and cardiac medical treatments during the study. 
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Table 2.4. Definition of terms used in clinical record 
Term Explanation 
Initial diagnosis 
date 
For a CHF cat it was defined as the date on which both primary 
CM (diagnosed based on echocardiography) and CHF (based on 
radiography and/or ultrasonography) were definitely diagnosed; 
for an asymptomatic CM cat it was defined as the date when 
primary CM diagnosis was made based on echocardiography. 
Survival days Survival status of all CM cats was recorded during the study period. 
For non-survival cats, it was defined as date difference between 
initial diagnosis and date of death. For cats still alive by the end of 
the study or lost to follow up, date of last contact or last time the cat 
known to be alive was used and censored in statistical analysis. 
Cause of mortality (1) Cardiac cause: a cat which died naturally or euthanized due to 
refractory/uncontrolled CHF, or other cardiac disease related death 
such as arterial or pulmonary thromboembolism; (2) Non-cardiac 
cause: a cat which died naturally or euthanized due to unrelated 
reason (s) to cardiac disease.   
Overall CHF status 
(stable/unstable):  
 
‘Stable’ status was defined as during study period- (1) a ISACHC 
IIIa animal, alive, home management for CHF was sufficient 
(Porciello et al., 2016) and there was no known record of apparent 
CHF deterioration-i.e. progression to IIIb; OR (2) a ISACHC IIIb 
animal, alive, after initial hospital management for CHF, home 
management for CHF was sufficient and no re-hospitalization due 
to CHF; ‘Unstable’ status was defined as during the study period- 
(1) a CHF cat which died naturally or was euthanized due to cardiac 
reason; OR (2) there was apparent CHF deterioration (e.g. a cat with 
disease progressed from home management to hospital 
management) or hospital management always required at each visit.  
CHF severity grade 
(1-4 scales) 
CHF severity was graded based on ISACHC classification: 1 = no 
evidence of cardiac remodelling (ISACHC class IIa); 2 = evidence 
of cardiac remodelling (ISACHC class IIb); 3 = advanced CHF, 
home management (ISACHC class IIIa); 4 = advanced CHF, need 
hospitalization (ISACHC class IIIb) 
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Table 2.5. Echocardiography variables and evaluation method  
Echo Variable  Evaluation method 
LA diameter 2D mode. Right parasternal short axis view at the heart base. 
Measured at the end of diastole with all aortic valve leaflets closed, 
at the onset of the QRS complex. 
LA/Ao ratio 2D mode. Right parasternal short axis view at the heart base. 
Measured at the end of diastole with all aortic valve leaflets closed, 
at the onset of the QRS complex.  
LVFWd 2D or M-mode. Right parasternal views. Measured for maximal LV 
free wall thickness at the end of diastole, with leading edge to 
leading edge technique. 
IVSd 2D or M-mode. Right parasternal views. Measured for maximal 
interventricular septal thickness at the end of diastole, with leading 
edge to leading edge technique. 
LV FS% M mode. Right parasternal short axis of the left ventricle at the level 
of the chordae tendineae. Measured with leading edge to leading 
edge technique.  
Spontaneous echo-
contrast/intra-
cardiac thrombus 
2D mode. Right parasternal views and left cranial views of the left 
auricular appendage. Looked for evidence of cloud-like swirling of 
intra-cardiac blood or a thrombus. 
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2.5 Blood Sample Collection, Processing and Storage. 
CM cat blood samples were collected as soon as possible after the initial diagnosis was made. 
A volume of 0.3-1.5 ml of blood was sampled via venepuncture (in most case using jugular 
vein). Following collection, samples were allowed to clot and centrifuged at 9000 rpm for 3 
minutes at room temperature; serum was separated and collected into a new collection tube and 
stored in a -20°C freezer temporarily then transferred to a -80°C freezer for long term storage 
before batch analysis. Commercial healthy control feline serum samples followed the same 
storage protocol. 
 
2.6 Experimental Design  
Due to serum sample volume limitations and different sample volume requirements in each 
test, a prioritization of the biomarker tests was arranged prior to laboratory testing. Based on 
research interest, sample volume availability and laboratory test feasibility, tests were 
prioritised in the following order (with priority in descending order): NT-proBNP, SDMA, 
creatinine and APPs (LRG1, Hp, AGP, SAA, CRP, PCT and ceruloplasmin). 
2.6.1 Baseline Study in Three Cat Groups 
Blood samples from 35 CM cats (23 CHF cats and 12 asymptomatic CM cats) and 20 healthy 
control cats were used for the baseline study. A detailed allocation plan is illustrated in Figure 
2.2.  
 
2.6.2 Longitudinal Study in CHF Cats 
Sample collection for the longitudinal study was carried out in CHF cats between August 2016 
and August 2017. After initial baseline sample collection, cats enrolled during this time period 
had blood samples taken at subsequent revisits. By August 2017, 12 CHF cats had follow-up 
blood samples after the initial baseline sample collection. Among them, 12 cats were tested for 
CvRD markers and 9 cats were tested for APPs in the serial study
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Figure 2.2. Study subject allocation plan for the biomarker baseline study. Two panels of 
biomarkers were evaluated i.e. CvRD and Inflammation. Note: different numbers of cats were 
used for different analyses; this was due to serum sample volume limitations to meet all test 
requirements.  
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2.7 Measurements of CvRD Biomarkers 
For samples collected between 2016 and 2017, volumes of 200-330 ul serum were shipped to 
IDEXX Reference Laboratory (Germany) for biomarker analysis; NT-proBNP concentration 
was measured using the Cardiopet proBNP assay. SDMA was measured using the IDEXX 
SDMA assay and creatinine was measured using a kinetic colour test. Assay methods are listed 
in Table 2.6. Additionally, 9 samples (3 CHF and 6 asymptomatic CM) collected in 2014 had 
serum NT-proBNP values measured at time of collection using the same methodology at the 
IDEXX Reference Laboratory (UK). The NT-proBNP data from these cats was kindly shared 
by Iñigo Sanz González. These retrospective data were combined with the new NT-proBNP 
results in 2017 for statistical analysis. 
 
Table 2.6. Detection methods for NT-proBNP, SDMA and creatinine  
Biomarker Detection Method  Detection Range 
NT-proBNP Cardiopet proBNP  
(Enzyme-linked immunosorbent assay) 
24-1500 pmol/l 
SDMA Enzyme immunoassay 1-100 µg/dl 
Creatinine Kinetic colour test (compensated Jaffé reaction) 5-2200 µmol/l 
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2.8 Measurements of APPs 
Pre-frozen serum samples collected between 2014 and 2017 were shipped on dry ice to Dr 
Christopher Chadwick at Life Diagnostic Inc., USA for APPs tests. Spatial Proximity Analyte 
Reagent Capture Luminescence (SPARCLTM) assays were used for APP measurements (Table 
2-7). The principle of a SPARCL™ assay is as follows: each assay contains two specific 
antibodies with one conjugated to horseradish peroxidase (HRP) and the other conjugated to 
chemiluminescent substrate -acridan. Both antibodies target the same biomarker. In a reaction 
system, when the two conjugated antibodies bind to their target biomarker, HRP and acridan 
react and cause chemiluminescence which is proportional to target biomarker concentration.  
Prior to sample testing, APP standard solutions were prepared. The lyophilized APP stock was 
reconstituted with diluent (CSD50-1, Life Diagnostic Inc. USA) and mixed gently until 
dissolved. Eight standards were prepared for each APP. Depending on the specific APP, the 
following serial dilutions were used respectively: For AGP: 125, 62.5, 31.25, 15.63, 7.81, 3.91, 
1.95 and 0.98 ng/ml; CRP: 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.195 and 0.098 ng/ml; Hp: 50, 
25, 12.5, 6.25, 3.13, 1.56, 0.78 and 0.39 ng/ml; SAA: 100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 
0.78 ng/ml; PCT: 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39 and 0.20 ng/ml; LRG1: 1000, 500, 250, 
125, 62.5, 31.25, 15.63 and 7.813ng/ml; and ceruloplasmin: 200, 100, 50, 25, 12.5, 6.25, 3.13, 
1.56 ng/ml.  
Serum samples were diluted to different concentrations with the diluent provided (Table 2.7), 
depending on the nature of each assay. In the wells of a 96 well plate, 25 μl of mixed HRP and 
acridan conjugated antibodies were added, followed by 50 μl of standard solution or diluted 
sample. The plate was incubated for 30 min at 25°C and 150 rpm on a microplate incubator. 
After incubation, the plate was placed in a BMG LUMI star Omega luminometer (BMG 
LABTECH, USA). The luminometer was set up at a gain of 3600, primed with 1ml of trigger 
solution and the injection needle was positioned in the injection port in advance. Luminescence 
was immediately measured after injecting 37.5 μl trigger solution. A standard curve was 
calculated by plotting luminescence for the standards versus log 10 of each APP concentration 
using graphing software. Sample APP concentration was calculated from the standard curve 
by converting the luminescence data antilog. 
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Table 2.7. SPARCLTM assays used in the APP measurements 
APP Catalogue Number Species Serum Sample 
Dilution (fold) 
AGP AGP-SP-8 Feline 20,000 
CRP CRP-SP-8 Feline  125,000 
Hp Hapt-SP-8 Feline 50,000 
SAA  SAA-SP-8 Feline 1000 or 50,000 
PCT PCT-SP-4  Canine 40 
LRG1 LRG-SP-8 Feline 100 
Ceruloplasmin CER-SP-8 Feline 10,000 
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2.9 Data Analysis  
All biomarker test results and clinical data were summarized and organized in one Microsoft 
Office Excel Datasheet and, basic descriptive data analysis was performed using Microsoft 
Office Excel. Statistical analysis was kindly performed and shared by Professor Geoffrey 
Fosgate in the Faculty of Veterinary Sciences, University of Pretoria, Onderstepoort, South 
Africa.  
Prior to statistical analysis, natural logarithm, square root or rank transformations were 
employed to improve the data normality distribution. All quantitative data were presented 
descriptively as the median and interquartile range (IQR). For NT-proBNP data analysis, a 
result >1500 pmol/l was assigned the value 1501pmol/l; a result < 24 pmol/l was assigned the 
value 23pmol/l (Sangster et al., 2014). ANOVA and t tests were used to compare quantitative 
data between groups. Significant ANOVA results were followed by multiple pairwise t tests 
employing Bonferroni correction of post hoc P values. Categorical data were described using 
frequencies, proportions, and 95% mid-P exact confidence intervals (CI). Chi-square and 
Fisher exact tests were used to compare categorical data among groups. The correlation 
between variables was assessed using scatter plots and calculating Spearman’s rho. Cox 
proportional hazards models were used to estimate the association between biomarkers and 
other cat-level variables (Appendix 1) on survival time in CHF cats. Univariate screening 
models were used and all variables significant (P <0.20) were selected in a backwards stepwise 
process for evaluation in multivariable models. Spearman’s rho was used to evaluate 
collinearity between selected variables and the variable with the weaker univariate association 
was excluded when ρ <0.70. Biomarkers with P <0.20 in the univariate screening models were 
analysed in multivariable models; receiver-operating characteristics (ROC) analysis was used 
to identify the most accurate cut-off for identifying non-surviving cats using the largest Youden 
index. The variables were removed one-by-one based on the largest Wald P value until all 
remaining variables were significant at P <0.05. Interaction terms were not evaluated.   
MINITAB Statistical Software Release 13.32 (Minitab Inc, State College, Pennsylvania, USA) 
was used to evaluate the normality assumption for quantitative data, plot histograms, calculate 
descriptive statistics and perform the Anderson-Darling normality test. Categorical data 
analysis was performed in available freeware Epi Info, version 6.04 (CDC, Atlanta, GA, USA) 
and all remaining analyses were performed using commercial software IBM SPSS Statistics 
Version 24 (International Business Machines Corp., Armonk, NY, USA).  Statistical findings 
were interpreted at the 5% level of significance. Descriptive plots for the longitudinal study 
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were created using the ggplot2 package (Wickham, 2009) within R (R Foundation for 
Statistical Computing, Vienna, Austria. URL https://www.R-project.org/). 
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Chapter 3: Results 
3.1 Study Population  
In total 37 CM cats were enrolled in the study, with 25 cats in CHF and 12 cats showing no 
clinical signs i.e. asymptomatic CM. Signalment and body weight are summarized in Table 3.1. 
Healthy control cats were significantly younger than the CM cats (P <0.01). Domestic short 
hair was the predominant breed for both CHF and asymptomatic CM cats, accounting for 84% 
and 100% of the populations respectively. Breed information in the healthy control group was 
not available. For both CHF and asymptomatic cats, males were over-represented; overall the 
male proportion was 74%. There were no significant differences in sex, age and body weight 
between CHF and asymptomatic cats (P > 0.05). All the enrolled cats were free from 
hyperthyroidism and no evidence of systemic hypertension was documented in any of the 
enrolled cats; systolic BP records were available in 14 CHF cats and 9 asymptomatic CM cats, 
the values being 131 + 26 (range 80-170) mmHg vs 133 + 14 (range 110-160) mmHg 
respectively.  
Recorded comorbidities in CHF cats were diabetes mellitus (n = 1), concurrent respiratory 
disease (n = 2), suspected disseminated carcinomatosis (n = 1), tricuspid dysplasia due to 
suspected storage disease (n = 1) and 3rd degree AV block with pacemaker implanted (n = 1). 
In the asymptomatic CM cats one had a chronic benign cervical mass, two had mild periodontal 
disease and one cat had eosinophilia of unknown aetiology.   
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Table 3.1. Signalments and body weight in the study populations 
 CHF (n = 25) Asymptomatic (n = 12)  Healthy Control (n = 20) 
 
Age (years) 
 
8.1 + 4.7 (1.0-15.3) 
 
6.6 + 4.4 (0.7-14.3) 
 
4.3 + 3.0 (0.6-11.3) 
 
Breed  DSH (n = 21); 
British blue (n = 1); 
Ragdoll (n = 1); 
Siamese (n = 1); 
Bengal (n = 1) 
 
DSH (n = 12) NA 
 
Sex  Female (n = 8); 
Male (n = 17) 
Female (n = 3); 
Male (n = 9) 
Female (n = 10); 
Male (n = 10) 
 
Weight (kg) 4.9 + 1.7 (2.3-9.5) 5.7+ 1.4 (3.7-8.0) NA 
 
Statistical analyses between CHF and asymptomatic CM cats were performed for age (P = 
0.35), sex (P = 1.0) and weight (P = 0.177). Values of variables are presented as mean + 
standard deviation (range). DSH, domestic short hair; NA, not available. 
  
  
62 
 
3.2 Clinical Record Comparison in CM Cats 
Overall CM phenotypes were significantly different between CHF and asymptomatic cats 
(Figure 3.1). Compared with the asymptomatic group (n = 12), the CHF group (n = 25) shows 
more diverse types of cardiomyopathies, including 44% HCM, 28% UCM, 24% RCM and 4% 
DCM; in the asymptomatic group 92% cats were diagnosed with HCM, except one UCM. 
Additionally, HOCM was present in 4 CHF cats, and 2 cats had SAM; in asymptomatic CM 
cats, 8 had HOCM and 3 had SAM. 
 
  
Figure 3.1. Comparison of CM phenotypes in CHF and asymptomatic CM cats. The 
differences were statistically significant (P = 0.011).  
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Baseline cardiovascular parameters including physical examination findings, ECG and selected 
echocardiographic parameters were recorded in both the CHF and asymptomatic groups at each 
sample point (Table 3.2). Compared with the asymptomatic group, cats in CHF showed a 
significantly higher respiratory rate (P = 0.009), increased LA diameter (P <0.001), increased 
LA/Ao ratio (P <0.001) and decreased LV FS% (P = 0.001) (Table 3.2). No significant 
differences were found for the presence of an arrhythmia (either by auscultation or on ECG) or 
gallop sounds, heart murmur status, pulse deficit, heart rate, LVFWd or IVSd.  
Table 3.2. Comparison of clinical parameters in CM cats at admission 
 CHF (n = 25)  Asymptomatic (n = 12)   
Variable n/d PE* (Interval†) n/d PE* (Interval†) P value 
Irregular heart rhythm 10/18 0.56 (0.33, 0.77) 1/7 0.14 (0.01, 0.53) 0.090 
Gallop sounds audible 4/24 0.17 (0.06, 0.35) 0/12 0.00 (0.00, 0.22) 0.278 
Murmur present 12/19 0.63 (0.40, 0.82) 11/12 0.92 (0.65, 1.0) 0.108 
Murmur grade ≥ 3 9/19 0.47 (0.26, 0.69) 6/12 0.50 (0.23, 0.77) 0.886 
Pulse deficit 3/11 0.27 (0.07, 0.58) 1/8 0.13 (0.01, 0.48) 0.603 
Abnormal ECG 13 /20 0.65 (0.43, 0.83) 3/9 0.33 (0.09, 0.67) 0.226 
Heart rate (per min) 24/25 180 (165, 200) 12/12 169 (160, 195) 0.398 
Respiratory rate (per min) 25/25 44 (36, 60) 12/12 30 (20, 55) 0.009 
LA diameter (mm) 25/25 20.0 (16.5, 22.0) 12/12 13.0 (11.3, 15.0) <0.001 
LA/Ao ratio 25/25 2.34 (1.84, 2.56) 12/12 1.32 (1.26, 1.39) <0.001 
LVFWd (mm) 25/25 6.38 (5.21, 7.41) 12/12 6.15 (5.03, 7.67) 0.987 
IVSd (mm) 25/25 6.03 (4.54, 7.53) 12/12 5.23 (4.67, 7.73) 0.463 
LV FS (%) 25/25 37.0 (23.5, 47.0) 12/12 53.0 (44.5, 63.0) 0.001 
n/d, numerator/denominator; *PE, point estimate, corresponding to the proportion for 
categorical variables and the median for quantitative data. †Interval-95% CI for categorical 
data and IQR for quantitative data.
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3.3 Circulating Biomarker Expressions in CM and Health Cats 
Ten biomarkers were examined in the current study, including three associated with CvRD (i.e. 
NT-proBNP, SDMA and creatinine) and seven APPs (i.e. AGP, CRP, Hp, LRG1, SAA, PCT 
and ceruloplasmin) (Table 3.3).  
Serum NT-proBNP, SDMA and creatinine levels were increased in CHF cats. NT-proBNP 
clearly differentiated the three groups. Cats in CHF showed significantly higher NT-proBNP 
levels than asymptomatic CM and healthy cats (P <0.05). In the asymptomatic CM population, 
three cats had an NT-proBNP concentration less than 100 pmol/l. In serum samples from 
healthy controls, NT-proBNP was generally undetectable using the current test i.e. <24 pmol/l, 
except one healthy cat had a value of 29 pmol/l. Renal markers SDMA and creatinine were 
also significantly increased in CHF cats compared with healthy controls (P <0.05). SDMA was 
significantly higher in CHF cats compared with asymptomatic cats (P <0.05) but was not 
different between asymptomatic and healthy groups (P >0.05); creatinine neither differentiated 
CHF cats from asymptomatic cats, nor differentiated asymptomatic cats from healthy controls 
(P >0.05). In the CHF group, 61% cats demonstrated abnormal SDMA levels according to the 
IDEXX laboratory reference (SDMA >14 ug/dl), while for creatinine, 44% had abnormal 
serum concentration (creatinine >168 µmol/l). One asymptomatic cat and two cats in the 
control group showed serum SDMA values higher than 14 ug/dl; another asymptomatic CM 
cat had a creatinine value above the reference range. The remaining cats in both asymptomatic 
and healthy groups had normal renal marker values. SDMA and creatinine were not measured 
in 2 CHF cats due to insufficient sample volume. 
CHF cats had significantly different expressions of APPs LRG1, SAA and ceruloplasmin 
compared with other groups. LRG-1 was significantly higher in CHF cats compared with 
healthy controls (P <0.05), although no significant differences were detected between the CHF 
and asymptomatic groups or the asymptomatic and healthy groups; SAA was significantly 
increased in CHF cats compared with both asymptomatic CM cats and healthy cats (P <0.05); 
ceruloplasmin was significantly increased in CHF cats compared with asymptomatic and 
healthy counterparts (P <0.05). Regardless of cardiac disease status, there were no significant 
differences in AGP, CRP, Hp and PCT between groups. PCT concentration was zero in most 
cats (24/37), for the rest it was above zero, of which six cats were in CHF, two were 
asymptomatic CM and five were healthy controls. Additionally, serum troponin I levels 
(measured as part of their clinical investigations) were higher in CHF cats (n = 5) than in 
asymptomatic CM cats (n = 4) (P = 0.01).  
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Table 3.3. Comparison of serum biomarker concentrations in CHF, asymptomatic CM and healthy control cats  
 CHF   Asymptomatic   Healthy Control    
Biomarker n Median (IQR) n Median (IQR) n Median (IQR) P value* 
CvRD Profile        
  NT-ProBNP (pmol/l) 19 1293a (780, >1500) 11 282b (76, 532) 20 <24c (<24, <24) <0.001 
  SDMA(ug/dl) 14 18.5a (12.0, 23.0) 5 11.0 b (8.5, 13.5) 19 9.0b (8.0, 12.0) <0.001 
  Creatinine(µmol/l) 14 159a (117, 195) 5 127a, b (115, 181) 19 95b (80, 120) <0.001 
        
APPs        
  AGP (µg/ml) 15 302 (240, 626) 9 187 (147, 325) 16 290 (187, 454) 0.327 
  CRP (µg/ml) 15 360 (226, 509) 9 290 (187, 454) 16 316 (218, 388) 0.356 
  Hp (µg/ml) 15 239 (32, 321) 9 141 (117, 217) 16 163 (57, 231) 0.887 
  LRG1 (µg/ml) 15 8.9a (6.4, 10.8) 9 5.3a, b (4.3, 7.0) 16 3.3b (2.7, 4.4) 0.037 
  SAA (µg/ml) 15 1.34a (1.00, 11.27) 9 0.79b (0.56, 1.00) 16 0.75b (0.64, 1.07) 0.009 
  PCT (ng/ml) 15 0 (0, 50.6) 9 0 (0, 5.7) 16 0 (0, 20.0) 0.644 
  Ceruloplasmin (µg/ml) 15 326a (272, 419) 9 227b (194, 268) 16 283b (241, 312) 0.001 
        
Myocardial Injury         
  cTnI (ng/ml) 5 1.11a (1.03, 1.69) 4 0.37b (0.12, 0.64) 0  0.010 
 * Medians without superscripts in common were significantly different (P <0.05) based on paired t test with Bonferroni correction of P value. 
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3.4 Correlations Between Biomarkers and Clinical Variables 
Biomarker expression was compared between different diagnostic phenotypes in the 37 CM 
cats. No apparent differences in the expression of 10 serum biomarkers were observed between 
HCM, UCM and other CM phenotypes (P ≥ 0.05) (Table 3.4).  
Table 3.4. Comparison of serum biomarker concentrations among different CM phenotypes  
 HCM (n = 22)  UCM (n = 8)  Other* (n = 7)   
Biomarker n Median (IQR) n Median (IQR) n Median (IQR) P value 
CvRD        
NT-ProBNP (pmol/l) 20 536 (214, 1426) 8 1397 (900, >1500) 6 1089 (721, >1500) 0.054 
SDMA (ug/dl) 11 14.0 (11.0, 23.0) 7 20.0 (13.0, 21.0) 5 13.0 (11.0, 19.5) 0.599 
Creatinine (µmol/l) 11 154 (104, 185) 7 194 (161, 201) 5 116 (98, 151) 0.050 
APPs        
AGP (µg/ml) 18 252 (165, 629) 7 297 (239, 520) 3 407 (302, 416) 0.840 
CRP (µg/ml) 18 325 (234, 402) 7 394 (360, 711) 3 476 (193, 490) 0.577 
Hp (µg/ml) 18 187 (104, 332) 7 292 (32, 472) 3 286 (272, 492) 0.544 
LRG1 (µg/ml) 18 7.0 (5.0, 10.3) 7 8.9 (6.4, 10.8) 3 8.4 (6.4, 10.8) 0.768 
SAA (µg/ml) 18 1.0 (0.79, 3.21) 7 1.10 (0.73, 11.83) 3 1.48 (1.12, 1.70) 0.695 
PCT (ng/ml) 18 0 (0, 11.6) 7 0 (0, 12.4) 3 0 (0, 96.0) 0.980 
Ceruloplasmin (µg/ml) 18 272 (226, 391) 7 326 (263, 481) 3 468 (294, 652) 0.129 
*Combined group of DCM (n = 1) and RCM (n = 6). ‡Two group comparison was performed 
between HCM and non-HCM diagnoses. 
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Markers of interest in the current study showed various correlations with each other and with 
clinical variables (Table 3.5). Major findings are summarized as following:  
(1) All three CvRD markers were significantly correlated with each other, with moderate 
positive correlations (Rho = 0.401-0.615, P <0.01). Seven APPs showed variable correlations 
with each other, with most of them having significantly weak to moderate positive correlations 
(Rho = 0.288-0.610, P <0.05); significantly negative correlation was only observed between 
PCT and Hp. 
(2) Significant positive correlations were found between biomarkers of myocardial stress, 
APPs and myocardial injury. NT-proBNP showed weak to moderate correlations with AGP, 
LRG1, SAA and ceruloplasmin; also showed a strong positive correlation with cTnI. AGP and 
Hp showed significantly strong positive correlations with cTnI level.  
(3) Significant correlations were found between several biomarkers and clinical echo variables. 
In general, most of the biomarkers positively correlated with LA diameter and LA/Ao ratio and 
negatively correlated with LV FS. In particular, NT-proBNP showed moderate positive 
correlations with LA diameter, LA/Ao ratio and a negative correlation with LV FS; LRG1 
demonstrated similar correlation patterns to NT-proBNP with the above echo variables, and 
also moderate positive correlations with LA diameter and with LA/Ao ratio, and a negative 
correlation with LV FS. Ceruloplasmin was positively correlated with LA diameter and LA/Ao 
ratio. Hp and SAA were positively correlated with LA diameter. Creatinine was negatively 
correlated with LVFWd and LV FS; PCT was negatively correlated with LVFWd.  
(4) Significant positive correlations were found between the three biomarkers and disease 
severity: NT-proBNP had a moderate positive correlation with CHF grades (Rho = 0.489, P 
<0.001); SAA and ceruloplasmin was weakly to moderately correlated with CHF grades.  
(5) In these cat populations, age appeared to have a moderate effect on creatinine (Rho = 0.505, 
P <0.001) and a weak effect on LRG1 (Rho = 0.296, P = 0.028) and SAA (Rho = 0.363, P = 
0.006). No significant correlations were found between age and other biomarkers.   
(6) Significant correlations were found between several APPs and two of the renal parameters. 
SDMA was found to have a moderate positive correlation with CRP and Hp, and a moderate 
negative correlation with PCT; creatinine was found to have a positive correlation with CRP, 
LRG1 and SAA.  
  
68 
 
Table 3.5. Spearman’s rank correlation between measured biomarkers and clinical variables at each sampling period in all cats participated in the 
study  
 NT-proBNP SDMA Creatinine AGP CRP Hp LRG1 SAA PCT Ceruloplasmin 
Biomarker           
NT-proBNP 1 0.615 (<0.001) 0.454 (<0.001) 0.269 (0.049) 0.240 (0.080) 0.242 (0.078) 0.456 (0.001) 0.317 (0.020) -0.168 (0.224) 0.439 (0.001) 
SDMA 0.615 (<0.001) 1 0.401 (0.002) 0.277 (0.065) 0.543 (<0.001) 0.417 (0.004) 0.210 (0.167) 0.254 (0.092) -0.385 (0.009) 0.174 (0.254) 
Creatinine 0.454 (<0.001) 0.401 (0.002) 1 0.116 (0.448) 0.312 (0.037) 0.174 (0.253) 0.470 (0.001) 0.472 (0.001) -0.043 (0.778) 0.232 (0.124) 
AGP  0.269 (0.049) 0.277 (0.065) 0.116 (0.448) 1 0.145 (0.291) 0.421 (0.001) 0.288 (0.033) 0.474 (<0.001) -0.053 (0.702) 0.610 (<0.001) 
CRP 0.240 (0.080) 0.543 (<0.001) 0.312 (0.037) 0.145 (0.291) 1 0.257 (0.058) 0.394 (0.003) 0.402 (0.002) -0.134 (0.331) 0.291 (0.031) 
Hp 0.242 (0.078) 0.417 (0.004) 0.174 (0.253) 0.421 (0.001) 0.257 (0.058) 1 0.193 (0.158) 0.314 (0.019) -0.325 (0.015) 0.327 (0.015) 
LRG1 0.456 (0.001) 0.210 (0.167) 0.470 (0.001) 0.288 (0.033) 0.394 (0.003) 0.193 (0.158) 1 0.481 (<0.001) 0.420 (0.001) 0.342 (0.011) 
SAA 0.317 (0.020) 0.254 (0.092) 0.472 (0.001) 0.474 (<0.001) 0.402 (0.002) 0.314 (0.019) 0.481 (<0.001) 1 -0.022 (0.872) 0.527 (<0.001) 
PCT -0.168 (0.224) -0.385 (0.009) -0.043 (0.778) -0.053 (0.702) -0.134 (0.331) -0.325 (0.015) 0.420 (0.001) -0.022 (0.872) 1 0.085 (0.538) 
Ceruloplasmin 0.439 (0.001) 0.174 (0.254) 0.232 (0.124) 0.610 (<0.001) 0.291 (0.031) 0.327 (0.015) 0.342 (0.011) 0.527 (<0.001) 0.085 (0.538) 1 
cTnI 0.730 (0.017) 0.667 (0.219) 0.700 (0.188) 0.786 (0.036) -0.071 (0.879) 0.893 (0.007) 0.750 (0.052) 0.559 (0.192) 0.236 (0.610) 0.643 (0.119) 
 
Echo Variables           
LA diameter 0.528 (0.001) 0.324 (0.132) 0.165 (0.453) 0.300 (0.121) 0.297 (0.125) 0.422 (0.025) 0.537 (0.003) 0.420 (0.026) 0.053 (0.790) 0.429 (0.023) 
LA/Ao ratio 0.547 (0.001) 0.404 (0.056) 0.110 (0.617) 0.150 (0.447) 0.313 (0.105) 0.309 (0.110) 0.445 (0.018) 0.147 (0.456) 0.146 (0.460) 0.376 (0.048) 
LVFWd 0.133 (0.453) 0.030 (0.893) -0.453 (0.030) 0.174 (0.376) 0.099 (0.616) 0.208 (0.289) -0.109 (0.581) 0.243 (0.213) -0.562 (0.002) 0.204 (0.299) 
IVSd 0.084 (0.636) 0.072 (0.743) -0.004 (0.986) 0.224 (0.251) 0.239 (0.221) -0.007 (0.972) -0.011 (0.956) 0.204 (0.297) -0.216 (0.270) 0.193 (0.326) 
LV FS -0.428 (0.012) -0.362 (0.090) -0.468 (0.024) -0.171 (0.384) -0.333 (0.084) -0.302 (0.118) -0.388 (0.042) -0.229 (0.242) 0.003 (0.988) -0.201 (0.306) 
 
Others            
CHF grade 0.489 (<0.001) 0.305 (0.052) -0.035 (0.827) 0.309 (0.059) 0.044 (0.793) 0.221 (0.182) 0.213 (0.198) 0.345 (0.034) 0.079 (0.636) 0.405 (0.012) 
Age (sampling) 0.183 (0.123) 0.178 (0.175) 0.505 (<0.001) 0.059 (0.666) 0.175 (0.201) 0.162 (0.238) 0.296 (0.028) 0.363 (0.006) 0.136 (0.321) 0.247 (0.069) 
Diagnosis days 0.058 (0.683) -0.076 (0.635) -0.055 (0.734) -0.028 (0.863) -0.073 (0.657) 0.023 (0.890) -0.270 (0.096) -0.214 (0.191) -0.049 (0.767) 0.288 .075) 
Data presented as spearman’s rank correlation (P Value). Significant correlations are presented in bold font.
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3.5 Survival Analysis in CHF Cats 
Regarding presentation of CHF, 13 cats were diagnosed with pulmonary oedema and 17 cats 
with pleural effusion. Pericardial effusion and ascites were present in 6 and 4 cats respectively. 
Based on the ISACHC system, 64% cats were in ISACHC Class IIIa and 36% cats were in 
Class IIIb at admission. During the study period, 10 cats in CHF groups had thoracocentesis 
procedures (from 1-4 times). Seventeen CHF cats required stabilization in the ICU, with total 
stay time 4.3 + 3.6 days (range from 0.5-15 days). Eleven cats were considered as overall stable 
without apparent CHF deterioration during the study, and the other 14 CHF cats were classified 
as unstable which either died or had CHF deterioration during the study time. Concurrent 
arrhythmias in CHF cats included VPCs, atrial fibrillation, ventricular tachycardia, atrial 
premature complexes (APCs) and 3rd degree AV block. In total 11 cats had a risk or episode of 
thrombotic event: 9 cats had spontaneous echo contrast and 1 cat had an intra-cardiac thrombus 
on echocardiography; ATE occurred in one cat. All CHF cats received various combinations 
of cardiac medications prior to 1st blood sampling, including furosemide (1.0-13.8 mg/kg/24h), 
torasemide (0.2-1.0 mg/kg/24h), benazepril (0.2-1.0 mg/kg/24h), spironolactone (1.3-2.6 
mg/kg/24h), pimobendan (0.3-0.7 mg/kg/24h), clopidogrel (1.9-8.9 mg/kg/24h), aspirin (3.6-
8.0 mg/kg/72h), diltiazem (5.2-7.7 mg/kg/24h), sotalol (4.3-4.8 mg/kg/24h) and potassium 
supplementation. By November 2017, 12 cats in CHF were alive and the other 13 had died. 
Causes of mortality include 8 cardiac deaths, 1 suspected death from neoplasia and concurrent 
CHF, and 2 cats died with reasons unknown. 
Survival analysis was performed to identify potential prognostic factors for all causes of 
mortality in CHF cats. Initial analysis suggested five potential prognostic indicators for survival 
status in the CHF group (Table 3.6) i.e. LA diameter, LA/Ao ratio, LV FS, NT-proBNP and 
SDMA (P <0.05). Significantly increased LA diameters (P = 0.003), increased LA/Ao ratio (P 
<0.001) and decreased LV FS (P = 0.036) were found in cats that died compared with cats that 
survived. Of the biomarkers, NT-proBNP was significantly higher in non-survivors, with a 
median concentration of >1500 pmol/l (IQR 1308->1500) in non-survivors and 780 pmol/l 
(IQR 578-1477) in survivors. Similarly, significantly higher SDMA was found in the serum of 
non-surviving cats with median concentration at 21ug/dl (IQR 16.5-23.0), while in cats that 
survived the median SDMA level was 13.0 ug/dl (IQR 11.0-20.0) (P = 0.007). No significant 
differences (P > 0.05) were found between survivors and cats that died in creatinine and APP 
concentrations. 
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Table 3.6. Comparison of potential prognostic indicators determined at the time of admission 
for CHF cats. 
 Survived (n = 12)  Died (n = 13)   
Variable Median (n) IQR Median (n) IQR P value* 
Age at diagnosis (years) 9.6 (12) 4.9, 12.2 5.1 (13) 4.1, 13.1 0.906 
Weight (kg) 4.9 (11) 4.3, 6.8 3.8 (13) 3.3, 5.4 0.050 
      
Echo Variables      
  LA diameter (mm) 18.0 (12) 16.3, 21.0 21.0 (13) 17.5, 22.5 0.003 
  LA/Ao ratio 2.11 (12) 1.72, 2.54 2.36 (13) 2.03, 2.86 <0.001 
  LVFWd (mm) 6.15 (12) 5.44, 7.37 6.56 (13) 4.60, 7.70 0.729 
  IVSd (mm) 6.37 (12) 4.37, 8.94 6.00 (13) 4.68, 7.21 0.892 
  LV FS (%) 37.5 (12) 26.5, 48.3 30.0 (13) 21.0, 46.5 0.036 
      
CvRD Biomarkers      
  NT-ProBNP (pmol/l) 780 (11) 578, 1477 >1500 (12) 1308, >1500 0.001 
  SDMA (ug/dl) 13.0 (9) 11.0, 20.0 21.0 (9) 16.5, 23.0 0.007 
  Creatinine (µmol/l) 157 (9) 114, 201 161 (9) 111, 191 0.922 
      
APPs      
  AGP (µg/ml) 302 (9) 234, 477 459 (10) 248, 770 0.090 
  CRP (µg/ml) 476 (9) 274, 544 368 (10) 267, 439 0.937 
  Hp (µg/ml) 272 (9) 145, 361 307 (10) 24, 641 0.526 
  LRG1 (µg/ml) 9.4 (9) 7.8, 11.9 8.6 (10) 5.5, 11.3 0.940 
  SAA (µg/ml) 1.70 (9) 1.23, 14.09 1.11 (10) 0.84, 3.45 0.844 
  PCT (ng/ml) 0 (9) 0, 54.0 0 (10) 0, 21.9 0.938 
  Ceruloplasmin (µg/ml) 391 (9) 283, 487 372 (10) 289, 496 0.932 
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Univariate Cox proportional hazard analysis was performed to evaluate the effect of potential 
prognostic factors on survival time in the 25 CHF cats considering all causes of mortality 
(Table 3.7). Significant univariate predictors included unstable CHF (P = 0.018), arrhythmia 
detected by auscultation (P = 0.015), audible gallop sounds (P = 0.029), LA/Ao ratio (P = 
0.007) and serum AGP level (P = 0.007). Cats with unstable CHF had an increased hazard ratio 
of 12.0; presence of an arrhythmia and gallop sounds gave an increased hazard ratio of 14.1 
and 5.1 respectively. Insignificant (P <0.20, but > 0.05) univariate predictors included LA 
diameter, heart rate, murmur grade ≥ 4, presence of pulse deficit, arrhythmia on ECG, NT-
proBNP and SDMA level.  
Signalment variables were forced into multivariable models to account for potential 
confounding. Multivariable survival analysis (Table 3.8) suggested the following three 
variables are independent poor prognostic factors in the CHF cats (n = 19): body weight < 4.5 
kg, LA/Ao ratio ≥ 2 and serum AGP level ≥ 600 µg/ml were found to increase hazard ratios 
significantly (P = 0.023, P = 0.013 and P = 0.009 respectively). 
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Table 3.7. Univariate Cox proportional hazards analysis evaluating the effects of potential 
prognostic factors for CHF cats. Results are presented for signalment and only those other 
variables with P <0.20. 
Variable/level n 
Parameter 
estimate ( ) 
Hazards ratio 
(95% CI) 
P value 
(Wald) 
Signalment     
Age    0.501 
  <5 years 8 0.751 2.12 (0.51, 8.90) 0.305 
  5-10 years 7 0.825 2.28 (0.50, 10.4) 0.287 
  >10 years 10 Referent   
 
Sex     
  Male 17 -0.138 0.87 (0.28, 2.76) 0.815 
  Female 8 Referent   
 
Weight     
  <4.5 kg 11 0.431 1.54 (0.49, 4.86) 0.463 
  ≥4.5 kg 13 Referent   
     
Cardiac Variables     
LA diameter (mm)* 25 0.140 1.15 (0.99, 1.33) 0.064 
LA/Ao ratio* 25 1.131 3.10 (1.36, 7.05) 0.007 
Heart rate (bpm)* 24 0.019 1.02 (0.99, 1.05) 0.170 
Unstable CHF 25 2.486 12.0 (1.53, 95.5) 0.018 
Arrhythmia by auscultation 18 2.644 14.1 (1.68, 118) 0.015 
Gallop sounds 24 1.631 5.11 (1.18, 22.1) 0.029 
Murmur grade ≥4 19 1.349 3.85 (0.74, 20.0) 0.108 
Pulse deficit 11 1.434 4.20 (0.70, 25.3) 0.118 
Arrhythmia on ECG 20 1.792 6.00 (0.75, 48.4) 0.092 
     
Biomarkers     
NT-ProBNP* 20 0.002 1.002 (1.000, 1.005) 0.077 
SDMA* 18 0.088 1.090 (0.960, 1.250) 0.190 
AGP* 19 0.005 1.005 (1.001, 1.0029) 0.007 
*Variable analyzed as a continuous predictor. Bpm, beats per minute;  
ˆ
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Table 3.8. Multivariable Cox proportional hazards analysis evaluating the effects of potential 
prognostic factors for CHF cats.   
Variable/level n* 
Parameter 
estimate ( ) 
Hazards ratio 
(95% CI) 
P value 
(Wald) 
Signalment     
Age     
  <7 years 10 1.482 4.40 (0.39, 49.5) 0.230 
  ≥7 years 9 Referent   
     
Sex     
  Male 13 -0.528 0.59 (0.07, 5.19) 0.634 
  Female 6 Referent   
     
Weight     
  <4.5 kg 10 3.891 49.0 (1.71, 1402) 0.023 
  ≥4.5 kg 9 Referent   
     
Cardiac Variables     
LA/Ao ratio†     
  ≥2 12 4.682 108 (2.66, 4395) 0.013 
  <2  7 Referent   
     
Biomarkers     
AGP†     
  ≥600 (µg/ml) 5 3.695 40.2 (2.53, 641) 0.009 
  <600 (µg/ml) 14 Referent   
*Six cats had missing data in one or more of the analysed variables and therefore could not be 
included. †Cut-off for evaluation determined using a ROC curve analysis 
 
ˆ
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3.6 Longitudinal Biomarker Studies in CHF Cats  
From August 2016 to August 2017, 12 CHF cats had serial samples taken for biomarker 
measurements, at the initial visit and then at subsequent revisits, with from 2-5 serial samples 
collected over a time interval from 7-321 days after the first sample collection date. Six of these 
cats had died by November 2017 (the data collection stop point), the other six remained alive. 
Serial NT-proBNP Measurement in CHF Cats 
Overall, the serial NT-proBNP measurements show inconsistent patterns among the 12 CHF 
cats (Figure 3.2), however cats that died appeared to have higher NT-proBNP values than 
survivors. Details of measurements and the trend of change in each cat are summarized in Table 
3.9. Eight cats had a >1500 pmol/l NT-proBNP measurement at the initial visit, and all cats 
that died belonged to this sub-population. Knowing that NT-proBNP has high biological 
variability in cats, a more than 60% of change compared with the previous measurement was 
considered as a significant ‘increase’ or ‘decrease’ (Harris et al., 2017b). Despite varied revisit 
intervals and numbers of measurements, at subsequent revisits 67% of the cats that died had an 
NT-proBNP concentration persistently higher than 1500 pmol/l. In the survivor group, 80% of 
cats had stable or decreased NT-proBNP concentrations at the 1st follow up time point, with 
one cat as an exception with a high NT-proBNP value (Cat No.1). 
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Figure 3.2. Serial NT-proBNP measurements in CHF cats. Serum biomarker changing 
trends are illustrated along the time axis post initial diagnosis. No consistent patterns 
were evident in NT-proBNP longitudinal changes between cats, except the majority 
of cats that died had NT-proBNP values persistently higher than 1500 pmol/l. Each 
colour represents a different cat; triangles represent cats that died and solid circles 
represent cats that survived. 
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Table 3.9. Longitudinal data summary in CHF Cats-NT-proBNP  
CHF Survivor (n = 6) 
Cat ID  Day 0 Day 1-14 Day 15-30 Day 31-90 Day 91-180 Day 181-365 Overall Trend 
No.1 >1500     >1500 Persistently high 
No.2 578     633; 
530  
Stable 
No.4 213    45  ↓ 
No.7 882  982    Stable 
No.10 1477 578  1282   ↓↑ 
No.12 >1500   950   Stable or ↓ 
CHF Non-Survivor (n = 6) 
Cat ID Day 0 Day 1-14 Day 15-30 Day 31-90 Day 91-180 Day 181-365 Overall Trend 
No.3 >1500   950   Stable or ↓ 
No.5 >1500 692     Stable or ↓ 
No.6 >1500  >1500 >1500; 
>1500 
>1500  Persistently high 
No.8 >1500  >1500    Persistently high 
No.9 >1500 >1500     Persistently high 
No.11 >1500  >1500    Persistently high 
 
Serum biomarker changing trends post initial diagnosis were illustrated. Day 0 was defined as 
the 1st day of blood sampling. For the overall trend summary, a NT-proBNP value >1500 
pmol/l is described as ‘high’; a more than 60% positive or negative change from the previous 
measurement is described as ‘increased’ or ‘decreased’; less than 60% of concentration change 
from the previous measurement is described as ‘stable’; ↓, decreased; ↑, increased; ↓↑, firstly 
decreased then followed by an increase; ↑↓, firstly increased then followed by a decrease. 
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Serial SDMA and Creatinine Measurement in CHF Cats 
Similar to NT-proBNP, 11 of the 12 CHF cats had serial measurements of SDMA and 
creatinine, with 1-4 follow up time points.  In terms of trend of change in serial SDMA and 
creatinine measurement, there were no consistent patterns identified among the individual CHF 
cats for either of the markers (Figure 3.3).  
More than 70% of cats had consistent overall trends of changes between SDMA and creatinine 
(Table 3.10). When looking at single data pairs, however, discrepancy between SDMA and 
creatinine interpretation was identified. According to IDEXX laboratory’s SDMA and 
creatinine test reference ranges for detecting renal dysfunction (SDMA >14 ug/dl; creatinine 
value >165 umol/l), 9 pairs of conflicting data (* in Table 3.10) were identified between SDMA 
and creatinine. Among these 8 pairs showed abnormal SDMA but a normal creatinine value, 
the remaining one showed borderline normal SDMA but abnormal creatinine. Six cats were 
involved with those conflicting data pairs. Four cats were non-survivors and three of them 
showed high SDMA but normal creatinine at initial assessment.  
Additionally, cats in the non-survivor group showed higher values of SDMA; cats with one 
SDMA measurement >20 ug/dl all died in the current study, regardless of the time point.  
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Figure 3.3. Serial SDMA and creatinine measurements in CHF cats. Serum biomarker changing trends are illustrated along the time 
axis post initial diagnosis. No consistent patterns were evident in either marker’s longitudinal changes between cats. Each colour 
represents a different cat; triangles represent cats that died and solid circles represent cats that survived.  
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Table 3.10. Longitudinal data summary in CHF Cats-SDMA and creatinine         
Unit: SDMA-ug/dl; creatinine-umol/l. * SDMA and creatinine conflicting data pairs. Cat No.4 Day 0 data missing was due to a technical reason. 
SDMA >14 ug/dl or creatinine >165 umol/l was defined as ‘high’.  ID, identification; ↓, decreased; ↑, increased; ↓↑, firstly decreased then 
followed by an increase; ↑↓, firstly increased then followed by a decrease. 
CHF Survivor (n = 6) 
Cat ID  Day 0 Day 1-14 Day15-30 Day31-90 Day91-180 Day 181-365 Initial Assessment Overall Trend 
SDMA Cr SDMA Cr SDMA Cr SDMA CR SDMA Cr SDMA Cr SDMA Cr SDMA  Cr 
No.1 12  154         *15 *135 Normal Normal ↑ to high ↓ 
No.2 13 116          12; 
*17 
  90; 
*139 
Normal Normal ↑ to high ↓ ↑ 
No.4 / /       11 128   / / / / 
No.7 17 194   19 208       High High ↑ ↑ 
No.10 10 157 8 122   9 126     Normal Normal ↓ ↑ ↓ ↑ 
No.12 16 183     10 148     High High ↓ to normal ↓ to normal 
CHF Non-Survivor (n = 6) 
Cat ID Day 0 Day 1-14 Day15-30 Day31-90 Day91-180 Day 181-365 Initial Assessment Overall Trend 
SDMA Cr SDMA Cr SDMA Cr SDMA Cr SDMA Cr SDMA Cr SDMA Cr SDMA  Cr 
No.3 *20 *136         *21; 
31 
*165; 
211 
High Normal ↑ ↑ to high 
No.5 *14 *185 10 125         Normal High ↓ ↓ to normal 
No.6 21 274   22 223 22; 
22 
235; 
189 
*36 *116   High High ↑ ↓ to normal 
No.8 *19 *65   *22 *72       High Normal ↑ ↑ 
No.9 13 161 12 155         Normal Normal ↓ ↓ 
No.11 *25 *104   14 75       High Normal ↓ to normal ↓ 
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Serial APPs Measurement in CHF cats 
In total, 9 out of 12 cats had follow up samples measured for APP markers. Overall longitudinal 
changes of each APP were highly diverse among individual cats; no clearly consistent patterns 
were identified (Figure 3.4). Overall trends of change for each individual APP marker in each 
cat are summarized in Table 3.11. Each cat demonstrated a unique pattern of APP profile 
change. There was no apparent difference appreciated between survivors and non-survivors. 
For each APP change in the whole population: consistent with baseline measurements, PCT 
was largely undetectable in the longitudinal study with two cats as exceptions. For the rest of 
the biomarkers, Hp decreased or remain unchanged in the majority (7 out of 9) of cats 
especially in non-survivors; CRP, ceruloplasmin and LRG-1 decreased in 8 out of 9, 7 out of 
9 and 6 out of 9 cats respectively at the 1st follow up time point. AGP and SAA showed diverse 
changes among individual cats. 
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Figure 3.4. Serial APP measurements in CHF cats. Changing trends of seven APPs are 
illustrated along the time axis post initial diagnosis. In total, 9 out of 12 cats had follow up 
samples measured for APP markers. For the remaining three cats, two had one initial 
measurement, which was also included here. The changes of each APP were highly 
variable. Each colour represents a different cat; triangles represent cats that died and solid 
circles represent cats that survived. 
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Table 3.11. Longitudinal data summary in CHF Cats-APPs  
CHF Survivor (n=6) 
Cat ID AGP CRP Hp LRG1 SAA PCT Ceruloplasmin 
No.1 ↓ ↓ ↑ ↓ ↓ _ ↓ 
No.2 ⇵ ↓ ↓ ↓ ↓ _ ⇵ 
No.4 / / / / / / / 
No.7 / / / / / / / 
No.10 ↑ ⇵ ⇅ ↑ ↑ ↑ ↑ 
No.12 ↓ ↓ ↓ ↓ ↑ _ ↓ 
CHF Non-Survivor (n=6) 
Cat ID AGP CRP Hp LRG1 SAA PCT Ceruloplasmin 
No.3 ↑ ↓ ↓ ↑ ↑ _ ↓ 
No.5 ↓ ↓ ↓ ↓ ↓ _ ↓ 
No.6 ↑ ↑ ↓ ↑ ↑ ↓ ↑ 
No.8 ↑ ↓ ↓ ↓ ↓ _ ↓ 
No.9 ↓ ↓ _ ↓ ↑ _ ↓ 
No.11 / / / / / / / 
 
Day 0 was defined as the 1st day of blood sampling. Trends of change are summarized for each 
APP in each individual cat. Note each cat demonstrated diverse changing patterns among APP 
expression; except in Cat No. 5, all the APPs decreased in subsequent measurements compared 
with the measurements at the initial time point. Cats No. 4, No. 7 and No. 11 could not have 
serial APPs measured due to serum sample volume limitations; cats No. 7 and No. 11 had the 
Day 0 concentration measured but not at subsequent time points. In the APPs longitudinal study, 
there were 1-2 follow up time points (not including Day 0). ↓, decreased; ↑, increased; ↓↑, 
firstly decreased then followed by an increase; ↑↓, firstly increased then followed by a decrease.  
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Chapter 4: Discussion 
4.1 CvRD Occurs in Feline CHF 
To the authors’ knowledge, this is the first study demonstrating CvRD namely CvRDH to be 
present in CHF cats with primary CMs. The presence of this disorder is shown by significant 
over-expression of renal biomarkers SDMA and creatinine, and the cardiac biomarker NT-
proBNP in the CHF cats compared with normal controls. Moreover, all three markers were 
significantly correlated suggesting a close relationship between the two organ systems. 
The mechanism of CvRD has been proposed previously in a veterinary consensus statement 
(Pouchelon et al., 2015). In cardiac decompensation, reduced cardiac output leads to inadequate 
renal perfusion, activation of neurohormonal responses, endothelial dysfunction and passive 
venous congestion and these are suggested as potential factors contributing to renal dysfunction 
(Pouchelon et al., 2015). Renal insufficiency has been reported to be a common comorbidity 
in human heart failure (McClellan et al., 2002, Akhter et al., 2004). CvRD has been reported 
in dog mitral valve disease, particularly associated with CHF. The severity of heart disease was 
found to be significantly correlated with the severity of chronic renal disease, moreover the 
presence of CvRD was associated with poorer survival (Martinelli et al., 2016). Although 
CvRD has not been reported in feline CHF, renal azotaemia is known as a common feature in 
feline heart disease. One previous study showed that in a HCM cat population, the prevalence 
of azotaemia was around 60% (Gouni et al., 2008). Apart from the cardio-renal interplay, 
therapeutic agents for CHF, notably loop diuretics and ACE inhibitors are also thought to 
induce renal dysfunction through their pharmacological effect on intra-renal haemodynamics 
(Orvalho and Cowgill, 2017). 
Considering the high prevalence and significance of CvRD in CHF, monitoring renal function 
is essential especially for medically treated patients. Ideally renal function should be evaluated 
by measuring GFR, however the technique is not very practical in small animal medicine. 
Traditionally creatinine is used for renal functional staging. One major drawback of creatinine 
is that it only shows a significant increase in primary renal disease when there is 75% nephron 
functional loss (Relford et al., 2016). Moreover, it may be affected by a number of biological 
variables such as age and lean body mass (Miyagawa et al., 2010, Hall et al., 2014b). Novel 
renal markers with better sensitivity and specificity need to be developed in small animal 
medicine.  
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SDMA is a metabolite of amino acid arginine methylation (Kakimoto and Akazawa, 1970) and, 
like creatinine, it is associated with GFR in cats (Hall et al., 2014b) but is more sensitive in 
detecting early renal changes. In the current study the median SDMA level was found to be 
increased in CHF cats but the median creatinine level remained in the reference range; 61% 
CHF cats showed evidence of reduced GFR by increased SDMA while only 41% of the same 
population had increased creatinine. These findings were consisted with Hall and others’ study 
in 2014, in which SDMA was shown to increase when there was 25% loss of GFR and its 
detection of renal dysfunction was 17 months earlier than creatinine (Hall et al., 2014a). In a 
recent study on feline hyperthyroidism evaluating the ability of SDMA to detect ‘masked’ early 
renal disease without azotaemia, the sensitivity and specificity of SDMA was reported to be 
33% and 97% respectively (Peterson et al., 2018). In the most recent IRIS CKD guidelines, 
SDMA was included as a complementary test to creatinine for CKD staging (http://www.iris-
kidney.com/pdf/3_staging-of-ckd.pdf). In Hall and others’ study in 2014 (Hall et al., 2014b), 
SDMA appeared to increase in older cats with low GFR; in this study however, there was no 
age correlation with SDMA. It should also be noted that SDMA can increase in pre-renal 
azotaemia associated GRF reduction (such as dehydration and general anaesthesia), therefore 
when using SDMA as a renal functional marker, other clinical information should be 
considered for SDMA interpretation. 
Renal dysfunction is an independent prognostic factor in human heart failure (Hillege et al., 
2000; Hillege et al., 2006). Early recognition of kidney injury is essential for preserving kidney 
function. Therefore, SDMA should be used in feline CHF management, where early detection 
of renal impairment allows the clinician to adjust the treatment protocol.  
NT-proBNP is a useful marker in feline cardiology; the main function of NT-proBNP, which 
is released with myocardial stretch, is to protect against RAAS activation (Volpe et al., 2016). 
Previous studies suggested it can distinguish cardiogenic respiratory stress from primary 
respiratory disease and also differentiate different stages of cardiomyopathies (Borgeat et al., 
2015a). Consistent with findings in the literature (Connolly et al., 2008; Wess et al., 2009; Fox 
et al., 2011), in the current study NT-proBNP clearly differentiated CHF cats, occult CM cats 
and healthy controls. NT-proBNP was positively correlated with left atrial size; this has been 
reported by Connolly and others (Connolly et al., 2008) and can be explained by increased 
myocardial stretch in the left atrium during the disease process.  More interestingly, NT-
proBNP was also found to be negatively correlated with left ventricular systolic function; it has 
been shown that low left ventricular systolic function is associated with decreased survival time 
  
85 
 
in feline HCM (Payne et al., 2013). Together with positive correlations observed between NT-
proBNP and CHF severity, these indicate that high NT-proBNP might be associated with 
poorer outcome in feline CM. Indeed, in this study both NT-proBNP and SDMA were 
significantly higher in CHF cats that died compared with survivors, which suggested both 
markers potentially could predict survival, although neither remained significant in univariate 
or multivariate survival analyses models. The prognostic value of NT-proBNP is less 
investigated in cats compared with humans. A previous study had similar findings to ours in 
that NT-proBNP seemed to be a promising prognostic marker but did not show statistical 
significance in the multivariate survival analysis (Borgeat et al., 2014b). Investigation of the 
prognostic value of SDMA in small animal heart disease is very limited. One previous cat study 
compared SDMA expression in feline HCM, CKD and diabetes mellitus. SDMA seemed to be 
irrelevant in feline HCM, although the cardiac cat population used in that study was largely 
asymptomatic (Langhorn et al., 2017). In the current study, there were no significant SDMA 
changes between the asymptomatic CM cats and healthy controls. In a recent dog study, it was 
found to be increased in advanced stages of CHF in DMVD dogs (Choi et al., 2017). It should 
be noted that apart from reflecting GFR as a renal function marker, SDMA may play a role as 
a pro-inflammatory factor associated with endothelial dysfunction in feline CHF, based on 
previous human evidence (Schepers et al., 2011). The role and significance of SDMA in feline 
CM and CHF requires further investigation. Interestingly NT-proBNP is mainly eliminated by 
the kidney, thus the increased NT-proBNP may be a consequence of renal dysfunction rather 
than reflecting heart disease severity (Lalor et al., 2009), which further complicates the story. 
Future studies are necessary to clarify the prognostic characteristics of NT-proBNP and SDMA 
in feline CHF.  It should be noted that, as all the CHF cats had loop diuretic treatment at entry 
to the study, this would have an effect on biomarker expression particularly on the renal 
markers; this should be considered when interpret the results. However, regardless of whether 
treated for heart failure or not, elevated SDMA and creatinine should not be ignored in CHF 
cats. 
In summary, increased SDMA and creatinine supported CvRD being present in feline CHF. 
The results suggested SDMA should be added to kidney function monitoring protocols in CHF 
management. NT-proBNP and SDMA may have prognostic potential in feline CHF. 
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4.2 Inflammatory Biomarker APPs Increased in Feline CHF  
In this study seven positive APPs were screened as biomarkers of systemic inflammation. Four 
of them were found to be linked with feline CHF. LRG1 and SAA were significantly increased 
in CHF cats compared with control cats; ceruloplasmin was significantly higher in CHF cats 
compared with asymptomatic CM cats; serum AGP level was found to be associated with CHF 
cat survival. Moreover, those APPs showed significant positive correlations with cardiac 
biomarkers, echocardiographic variables such as LA size and CHF severity based on the 
ISACHC system. All these findings suggest systemic inflammation plays a role in feline CHF. 
Although inflammation has been recognized in heart failure patients for a long time, the 
mechanism was not well defined (Dick and Epelman, 2016). A recent review suggested that a 
reciprocal relationship might exist between heart failure and inflammation (Van Linthout and 
Tschope, 2017). Circulating inflammatory mediators such as APPs have been found to be 
predictive of adverse outcome in a number of human heart failure studies (Dick and Epelman, 
2016). APPs by definition are a group of by-products released during acute phase reactions in 
response to pathological insults, helping to restore physiological haemostasis (Ceron et al., 
2005). They are highly sensitive in response to tissue injury but lack specificity, therefore a 
multiple APP profile based approach is considered more accurate than single marker based 
investigation (Ceron et al., 2008). This pilot study is the first report using a multiple APP 
screening approach to demonstrate their involvement in feline CHF and our findings potentially 
indicate directions for future research, especially in improving understanding of the 
pathogenesis of this complex syndrome.  
There were discrepancies in the APP expression patterns in the CHF group. For example, LRG-
1 and ceruloplasmin were significantly higher in CHF cats, whereas CRP and Hp were not 
significantly different in CHF cats. Apart from knowing that there are species differences in 
APPs (Ceron et al., 2005), the differential expression of the APPs may also suggest that 
potential pathophysiological pathways differ in feline CHF. In particular, the correlations of 
LRG1, ceruloplasmin, SAA and AGP with cardiac biomarkers and echo variables such as left 
atrial size indicate their specific cardiac involvement, rather than purely serving as systemic 
inflammatory markers. 
LRG1 is a relatively novel APP in cardiovascular research. The detailed biological function of 
LRG1 is not very clear. It has been found to be associated with inflammation, neutrophil 
differentiation and may potentially play a role in angiogenesis and myocardial fibrosis by 
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interacting with TGF-β (Song and Wang, 2015; Kumagai et al., 2016). It was found to be 
increased in human diastolic heart failure, independently detected heart failure and was found 
to be superior to BNP (Watson et al., 2011). In an experimental induced myocardial infarct 
study in mice, LRG1 was shown to have a protective function against adverse cardiac 
remodelling (Kumagai et al., 2016). In the current study, the positive correlations between 
LRG1, left atrial size and NT-proBNP suggested an intrinsic cardiac involvement of LRG in 
feline CHF and CM. The specific role of this marker in the disease requires further investigation. 
Ceruloplasmin is a copper transporter involved in iron detoxification. It also has multiple links 
with oxidative stress (Ceron et al., 2005; Cabassi et al., 2014). In humans, this APP was found 
to predict adverse cardiovascular events (Ahmed et al., 2012) and it has been shown to associate 
with heart failure development and can independently predict all causes of mortality in heart 
failure patients (Kaya et al., 2013; Hammadah et al., 2014). In the current study ceruloplasmin 
was significantly higher in CHF cats compared with asymptomatic CM and healthy controls 
and it was positively correlated with CHF severity. Similar to LRG-1, veterinary data on 
ceruloplasmin are very limited. One interesting feline heart worm study found ceruloplasmin 
was significantly increased in symptomatic cats that were seropositive for Dirofilaria immitis 
(Silvestre-Ferreira et al., 2017). 
SAA is a small serum hydrophobic apolipoprotein, traditionally considered to be secreted in 
the liver, but more recent research suggests it can also be produced by adipose tissue and it 
may play a role in adipose inflammation (Yang et al., 2006). It has been considered as an 
inflammatory marker in cats for more than a decade and it is the most rapidly responsive major 
APP in cats (Sasaki et al., 2003). It has been found to increase in sick cats, hospitalized cats 
and cats with various disease conditions (Kajikawa et al., 1999; Kann et al., 2012; Tamamoto 
et al., 2013). One study suggested SAA has independent prognostic value in diseased cats with 
any diagnosis (Tamamoto et al., 2013). In the current study, SAA differentiated the CHF cats 
from asymptomatic CM cats and healthy control cats but failed to differentiate asymptomatic 
CM from healthy cats. This suggests SAA up-regulation particularly associated with feline 
CHF rather than compensated CM. Considering all the CHF cats were in advanced stages of 
heart failure i.e. ISACHC III and more than a third of the CHF cats required hospitalization at 
the time of blood sampling, it is not surprising SAA increased in this population. However, the 
specific connection of SAA with feline heart disease remains unclear. A recent research 
abstract reported SAA was significantly increased in asymptomatic feline HCM, specifically 
in 11 cats with generalized left ventricular hypertrophy, which indicated an involvement of 
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SAA in the early stages of feline CM (Van Hoek et al., 2018a). In humans, SAA has been 
associated with atherosclerosis and in a selected study population with coronary artery disease, 
it turned out to be an independent predictor for adverse cardiovascular events (Johnson et al., 
2004). In Kann et al, 2012’s study, age has been pointed out as a factor that can contribute to 
SAA increase (Kann et al., 2012), in the current study, a weak correlation was found between 
age and SAA level. Our healthy controls were significantly younger than the CHF and 
asymptomatic CM cats, but there was no significant difference in SAA expression between 
healthy control and asymptomatic CM, thus age is unlikely to have a dominant effect. Similarly, 
a gender influence was pointed out in the same study, but it was not evaluated in this study. 
AGP is one the three best studied APPs in cats and it is well known as being useful for 
discriminating FIP (Paltrinieri et al., 2007; Hazuchova et al., 2017). In this study, serum AGP 
was not found to be significantly elevated in the CHF cats compared with controls, however a 
strong correlation with cTnI and a weak correlation with NT-proBNP was also identified for 
serum AGP, which suggested a potential cardiac connection. A more exciting finding was in 
hazard risk analyses, where it seemed to be an independent risk predictor for all causes of 
mortality in the CHF cat population. In humans, this APP has been shown as an independent 
prognosticator for cardiovascular mortality as well as all causes of mortality (Fischer et al., 
2014), although in a later study it was suggested that AGP was not superior to CRP in predicting 
all causes of mortality (Singh-Manoux et al., 2017). A recent cat study investigated the value 
of AGP in distinguishing pleural effusions caused by feline FIP, cardiac disease or neoplasia. 
Lower AGP expression, together with lower Hp and SAA was found in cardiogenic effusion 
cases compared with infectious disease and neoplasia. A limitation of that study was that no 
healthy controls were included (Hazuchova et al., 2017). 
CRP is the most commonly studied major APP in humans and in the dog, however its value 
seems limited in feline patients (Ceron et al., 2005). In human medicine, it is well accepted as 
a prognostic indicator for predicting mortality risk in heart failure patients (Singh-Manoux et 
al., 2017). Previous dog studies also showed CRP to be increased in CHF and its elevation was 
associated with severity (Cunningham et al., 2012; Domanjko Petric et al., 2018). In the current 
study it did not detect any link between CRP and feline CHF.  
Hp is considered to be a moderate APP in cats (Ceron et al., 2005). Biologically it is involved 
in detoxification of haemoglobin as well as being an inflammatory reactant (Wassell, 2000). A 
specific Hp genotype in humans has been found to be associated with cardiovascular risk in 
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diabetes mellitus (Suleiman et al., 2005). In a large scale prospective human study, Hp was 
found to be a risk factor in heart failure (Holme et al., 2009). Its significance in veterinary 
cardiovascular diseases is not well established. In one canine DMVD study, Hp elevation was 
found in dogs that developed CHF (Polizopoulou et al., 2015). 
PCT is an acute phase reactant most commonly associated with sepsis (Giunti et al., 2006), but 
there is no available cat data for this APP. In this study, the PCT assay was developed for 
canine use, the species differences in this marker between dogs and cats are unknown. The fact 
that PCT was largely undetectable in the current study population could therefore be either a 
genuine biological feature or due to a technical limitation. PCT has been recently linked with 
heart failure in humans (Canbay et al., 2015; Mockel et al., 2017). In a small case controlled 
retrospective study, it showed reasonable sensitivity and specificity for CHF diagnosis (Canbay 
et al., 2015). 
The APPs provided valuable information for feline CHF, however the findings should be 
interpreted with caution for the following reasons: Firstly, APPs are well known as sensitive 
biomarkers but very non-specific. In this study, relatively strict exclusion criteria were used, 
however as most CHF cats were relatively old and commonly had multiple comorbidities, the 
possibility of occult comorbidity cannot be eliminated, which therefore might affect the current 
results. Secondly, biological variables may affect the APP expression; for example, both LRG 
and SAA showed a weak positive correlation with age in the current study. Given the fact cats 
in the CHF group were significantly older than healthy controls, age effects might have 
contributed to the differential expression between CHF cats and healthy controls for these two 
markers. More studies are necessary to clarify the effect of biological variations in APP 
expression. An age matched control population would be ideal to use for consolidating current 
findings on these two APPs. Lastly, most feline APP tests are not currently standardised, which 
results in inconsistent cut-off values between different techniques (Kann et al., 2012). In the 
current study the hazard analysis model predicted AGP >600 µg/ml had significantly higher 
risk than cats with lower AGP values. Based on the results, AGP is a promising risk predictor 
for feline CHF, however it is not recommended using this marker as a sole test of feline CHF 
prognosis at this stage, particularly in using the 600 µg/ml cut-off for clinical prognostic 
assessment when a different test method is used. APP assays used in this study were validated 
in cats. Test standardization is essential to establish in the future for using a specific APP for 
disease diagnosis and prognosis.  
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In summary, an inflammatory response appears to play a role in feline CHF and LRG1, SAA, 
ceruloplasmin and AGP may be used as novel biomarkers for feline CHF. The detailed role of 
these APPs in feline CHF requires further investigation, but they might help to understand the 
disease pathogenesis and be potentially useful for disease prognosis in combination with other 
clinical assessments.  
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4.3 The Relationships Between CvRD biomarkers and APPs 
In this study, it has shown that there were correlations between the CvRD biomarkers and APPs, 
which suggested CvRD and the inflammatory process may potentially interact with each other 
in feline CHF. The significant correlations between the two panels of markers included: NT-
proBNP positively correlated with AGP, LRG, SAA and ceruloplasmin; cTnI had strong 
positive correlations with AGP and Hp; SDMA had moderate positive correlations with CRP 
and Hp and creatinine positively correlated with CRP, LRG1 and SAA. 
The complex relationship between CvRD and inflammation is yet to be fully understood. 
Possible mechanisms include RAAS response and activation of cellular immunity (Schefold et 
al. 2016). A recent study showed systemic inflammation plays a role in feline chronic renal 
disease (Javard et al., 2017). 
It should be noted that some biomarkers may have additional functions besides serving as a 
marker of CvRD or inflammation. For example, apart from reflecting renal function, SDMA is 
also considered to play a part in the NO pathway and endothelial dysfunction (Dimitrow et al., 
2007; Cunningham et al., 2012; Mommersteeg et al., 2016) and serve as a pro-inflammatory 
factor in kidney disease (Schepers et al., 2011). Further investigations on specific biomarker 
function would be necessary to define their precise roles in heart disease.  
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4.4 Feline CM Phenotype and Biomarker Expression  
One interesting finding in this study was that feline CM phenotype did not affect the expression 
of any investigated biomarker. This information is valuable for future feline CM studies, as 
these biomarkers can potentially serve as universal tools in studying different types of 
cardiomyopathy.  
It is well accepted that the current feline CM phenotypic classification system is equivocal. As 
the classification system is based on anatomical change and the disease course is dynamic, 
sometimes it is difficult to reach a definitive diagnosis of CM subtype based on 
echocardiography (van Hoek et al., 2018b). This is particularly a challenge in CHF patients. In 
this study, heterogeneity was observed in CM diagnosis, with more diverse phenotypes in the 
CHF than in the asymptomatic group. Once a cat develops CHF, regardless of the primary CM 
phenotype, the treatment strategy is similar. In terms of disease prognosis however certain CM 
types are reported to have a worse prognosis than others (Pion et al., 1992; Ferasin et al., 2003). 
The equivocal classification system may hinder accuracy of disease prognosis. Most previous 
studies have focused on HCM which is the most common and readily recognized phenotype, 
while limited work has been done on RCM, UCM or ARVC. Findings in HCM studies may 
not be always translatable to other types of CM. 
Using serum biomarkers can potentially overcome the above limitations related to CM 
diagnosis and research focus, as they have less bias and thus may give a more accurate 
reflection of disease status and progression.  
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4.5 Clinical Examination Parameters Can Be Helpful Tools for 
Monitoring Feline CHF  
Apart from serum biomarkers, some relevant clinical parameters were also evaluated in the 
diseased population. Some of the cardiovascular physical examination parameters can be useful 
for disease monitoring and prognosis. 
Respiratory rate during physical examination was found significantly higher in CHF cats than 
in asymptomatic CM cats in the current study. Considering the ‘white coat’ effect during 
hospital visits (Quimby et al., 2011), respiratory rate is a more valuable monitoring tool in cats 
for CHF surveillance at home. Previous reports suggested a sleeping or resting respiratory rate 
persistently higher than 30 breaths per minute at home should be investigated for potential 
progression from sub-clinical heart disease to decompensated heart failure (Ljungvall et al., 
2014). The same cut-off also can be used to assess whether CHF is well controlled in cats 
(Porciello et al. 2016). In a recent study investigating feline RCM, respiratory distress was 
identified as an independent poor prognosticator in RCM which emphasizes the importance of 
this physical variable in cardiac disease clinical management (Locatelli et al., 2018). 
Arrhythmia and gallop sounds detected by cardiac auscultation showed potentially prognostic 
value for feline CHF in this study. These findings were consistent with previous studies (Smith 
and Dukes-McEwan, 2012; Payne et al., 2015a). Audible gallop sounds have been considered 
a relatively specific indicator for feline cardiac disease; in CHF cats, the prevalence was 
reported to be approximately 20-50% (Goutal et al., 2010; Smith and Dukes-McEwan, 2012; 
Dickson et al., 2018). Other physical examination parameters such as heart rate and heart 
murmur were not significant prognostic factors in feline CHF in the current study.  
Another significant physical examination parameter which potentially has prognostic value is 
body weight. Body weight was an independent risk predictor in CHF cats in the final 
multivariate analysis. CHF cats with a body weight less than 4.5 kg had at least 1.7 times higher 
risk of death than those heavier than 4.5 kg. In humans, loss of weight and body lean mass are 
significantly associated with poorer outcome in chronic heart failure (Pocock et al., 2008). In 
Finn and others’ 2010 study, body weight was a significant predictor of survival time in CHF 
cats (Finn et al., 2010). Weight loss associated with cardiac cachexia is considered to be a 
logical explanation for poorer survival, however it was suggested in the same study that both 
highest and lowest body weight may be associated with poorer clinical outcome in CHF cats 
(Finn et al., 2010). Balanced nutrition management and having a weight target maintained in 
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the normal physiological range is probably the most sensible strategy for feline chronic disease 
patients (Freeman et al., 2016). 
The value of echocardiographic parameters in feline CM prognosis has been well recognized 
in previous studies (Peterson et al., 1993; Fox et al., 1995; Payne et al., 2010; Payne et al., 
2013). Consistent with most of the previous reports, CHF cats in this study had more severe 
LA enlargement and poorer LV systolic functions than asymptomatic CM cats; moreover, these 
parameters were significantly higher in CHF cats that died, suggesting the two parameters 
correlated with disease severity. LA/Ao ratio particularly remained significant in both 
univariate and multivariate survival analyses. LA/Ao ratio higher than 2:1 was an independent 
risk factor in CHF cats. This finding fits the current clinical impression that LA remodelling 
has generally been considered as a very important marker for disease severity and progression 
in feline CM (Payne et al., 2013).  
In summary, several clinical variables showed prognostic value for feline CHF. With more 
advanced diagnostic techniques becoming available in small animal cardiology, the power of 
the basic cardiovascular examination should not be neglected (Dickson et al., 2018). A 
combination of objective clinical parameters and biomarkers could be very helpful for disease 
risk assessment.  
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4.6 Longitudinal Biomarker Studies in CHF Cats- What Did We Learn?  
In the second part of this study, longitudinal investigations were carried out in 12 CHF cats to 
assess the biomarker changes. Preliminary data were obtained, and no definitive conclusion 
can be drawn at this stage, but findings suggest some directions for future work such as that 
temporal monitoring of some biomarkers can potentially predict survival in CHF cats. 
Persistently high NT-proBNP (>1500 pmol/l) appeared to be a risk factor in feline CHF. At the 
initial visit, eight out of 12 CHF cats had serum NT-proBNP >1500 pmol/l, six of these died 
within 321 days. Over 65% of the cats that died had persistently high NT-proBNP at subsequent 
visits. This suggested high NT-proBNP may serve as a disease severity alert in CHF. NT-
proBNP has been used for heart disease prognosis in human medicine; as mentioned previously, 
its prognostic value in feline heart disease has not been well established. One recent 
longitudinal study in CHF cats showed a better outcome was linked with a greater reduction of 
NT-proBNP during hospitalization (Pierce et al., 2017). The challenge of NT-proBNP study 
design is the high biological variability in the cat.  A 39.8% daily variability and 60.5% weekly 
variability has been reported to occur in adult healthy cats, for longitudinal assessment only a 
change above 60% should be considered as significant (Harris et al., 2017b). This should be 
considered in study design and data interpretation.  
The longitudinal study of SDMA further confirmed the baseline study finding. It increased 
earlier than creatinine and high SDMA was associated with poor outcome. Although SDMA 
and creatinine values were compatible in most cases, nine pairs of conflicting data were spotted 
between SDMA and creatinine, among which eight pairs showed abnormal SDMA but normal 
creatinine. The longitudinal study showed SDMA detected renal injury earlier than creatinine 
in chronic CHF management. Cat No. 3 in the non-survivor CHF group is one classic example. 
At initial diagnosis the cat had a high SDMA value but normal creatinine value. After at least 
six months, creatinine started to increase. According to IDEXX recommendations, SDMA 
greater than 20 ug/dl requires immediate action (www.idexx.com/SDMAalgorithm). In the 
current SDMA temporal follow up, cats that had SDMA higher than 20 ug/dl all died regardless 
of measuring point. This further emphasized that renal protection should be carried out 
promptly when there is diagnostic evidence of kidney dysfunction. A previous study has shown 
SDMA started to increase when there was 25% glomerular damage. From the current results, 
it seems the renal injury at this stage is potentially reversible. Two cats (Cat No. 11 and Cat 
No. 12) demonstrated significant reduction of SDMA over time. In summary, preliminary data 
suggests longitudinal monitoring of SDMA is beneficial for heart failure management. It is a 
  
96 
 
valuable alternative kidney function marker to creatinine in CHF management, especially in 
cases where body lean mass is low.  
The APP profile measurements were also tracked in a longitudinal manner. In general, the pilot 
data suggested most APPs seem to decrease over time, but APP changes in individual cats were 
very heterogeneous. Each cat also demonstrated a unique pattern of APP profile change. This 
reflected the sensitive and dynamic nature of serum APP expression. The longitudinal study of 
APPs was particularly challenging because: (1) they are known to be very sensitive biomarkers; 
(2) their full biological functions are not clear; (3) biological variability may affect 
interpretation; (4) they might be affected by occult/concurrent inflammatory conditions so their 
changes may be non-specific; (5) the timing of sample collection may be critical as major APPs 
peak and decline rapidly after insult so inconsistent long term time points will inevitably cause 
inconsistent results. There is a need for APP longitudinal studies (Eckersall and Schmidt, 2014); 
they could be used as valuable surveillance tools in the future and it would be worth looking at 
the correlations between clinical signs and patient’s biomarker levels in a temporal manner 
(Tamamoto et al., 2009). For example, it would be interesting to assess if there is correlation 
between relapse of CHF and APP changes at subsequent re-visits compared with initial 
measurements. This future direction will potentially assist more advanced understanding of the 
role of APPs in feline CHF. A larger scale study, with fixed assessment time points associated 
with a particular CHF event would be helpful for assessing APP’s role in surveillance and 
prognosis. 
Apart from the small number of CHF cats in the study (n = 12), there were other limitations in 
the current longitudinal study design. The varied sampling points were not expected in the 
original study design. In the research proposal, fixed time points-Day 0, Day 14, Day 90 and 
Day 180 were planned for longitudinal data sampling, however, owners’ compliance with 
scheduled revisit times was very poor. In a future study it may be worth thinking of ways to 
improve this. The discrepancy of initial diagnosis and initial sampling dates in several animals 
confused survival analyses; ideally the two dates should be identical. Additionally, short term 
changes may be worth evaluating prior to a long term dedicated study. For example, biomarker 
levels at admission compared with at discharge will give information on how biomarkers 
respond to changing disease status. More work with a larger cat population and more 
comprehensive time points are needed for a longitudinal study.   
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4.7 Limitations 
There are several limitations in the current study; based on their associations, they can be 
divided into three aspects: study population, experimental techniques and study design.   
In terms of study population, firstly it is a small-scale study with clinical cases collected in one 
cardiology referral service. The study population may not be fully representative, although the 
study population characteristics showed classic features of feline CM which were reported by 
previous relevant studies. A statistical power calculation was not performed in the current study, 
as it was unrealistic to achieve due to limited sample collection time and availability. Although 
the current sample number is justified for statistical comparisons, the small sample size could 
affect statistical power in particular in the survival analysis model. Power calculation would 
worth performing in the work arising from this pilot study. Due to the limitation of the current 
CM classification system and the dynamic nature of disease progression, accurate diagnosis of 
CM phenotype was difficult to achieve; both intra-observer and inter-observer agreement may 
be inconsistent. To best overcome this issue, the final phenotypic classification was ratified by 
one senior ECVIM boarded cardiologist. Despite the classification issue, in the current study 
there were no significant differences in targeted biomarkers among different CM diagnosis 
categories.  
The exclusion criteria were mainly based on clinical records, which was not ideal particularly 
for ruling out renal disease and inflammatory comorbidities. Ideally complete urinalysis should 
be performed to look for inappropriate urine specific gravity, proteinuria or other evidence of 
kidney disease. Occult inflammatory conditions were challenging to detect unless all the 
candidate cats went through exhaustive clinical diagnostic testing, which was unrealistic to 
achieve in the current study. The known comorbidities of the study population might have 
effects on biomarker expression; for example two cats in the asymptomatic group had mild 
periodontal disease, which may potentially affect the inflammatory marker expression. Ideally 
these cats should be excluded.  Another flaw of the current study was that the systolic BP record 
was missing in 11 CHF and three asymptomatic CM cats. Systemic hypertension was one of 
the exclusion criteria in this study; unfortunately not all the cats had a record available, which 
is not an uncommon scenario in the clinical setting. Therefore the exclusion for hypertension 
was performed as far as was practically possible. The reasons for missing BP values include 
cats being too stressed for BP measurements at presentation, but having no other clinical signs 
indicating systemic hypertension, or cats had a BP measured by the referring veterinary 
surgeon. Also most of these cats were younger than eight years, when they were considered 
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less likely to be hypertensive (Borgeat et al., 2014b). However, systemic hypertension cannot 
be completely ruled out in those cats.  
Another limitation of the current study population is that the effect of medications on biomarker 
expression was not assessed. This was an issue particularly for the CvRD study, as it is known 
that loop diuretics can affect renal function, which can contribute to CvRD biomarker elevation. 
It should be noted that the effect of loop diuretics on renal function in CHF patients is like a 
“double edged sword”: effective decongestion with diuretics would be beneficial for the kidney 
(Orvalho and Cowgill, 2017). Ideally an untreated CHF population should be used to assess 
CvRD; however, this is difficult to achieve in a cardiology referral clinic. Also, from a practical 
point of view, regardless of whether medical therapy was used or not, kidney function 
monitoring should be addressed in CHF cats. 
Lastly, the serum samples from healthy control cats used in the current study were obtained 
from a commercial source; therefore, the full clinical history of these cats was not accessible. 
Echocardiography was not performed in this group, although the serum NT-proBNP test results 
suggested that occult heart disease was unlikely. The presence of other non-cardiac occult 
disease cannot be ruled out, however. In fact, the sporadic high values in SDMA and several 
APPs in some cats might indicate the presence of underlying conditions, but this pitfall is less 
likely to confound the current conclusions. Another issue with the healthy control population 
was that the cats were significantly younger than the CHF and asymptomatic groups. The age 
effect on biomarker expression cannot be eliminated in the current study.  
One major limitation related to serum samples was retrospective acquisition in some animals. 
For the baseline APP study, nine serum samples were selected retrospectively from service 
archives. These samples were originally collected in 2012-2014 and long term storage effects 
on biomarker expression was not evaluated in the current study. Inadequate serum sample 
volume was another limitation; three candidate cats could not have biomarkers measured due 
to this issue. In future studies, fluid from a body cavity (e.g. pleural effusion) could be 
considered as an alternative for systemic biomarker measurement (Hazuchova et al., 2017), 
which may be easier to collect, especially in critical patients. For NT-proBNP tests, values 
were not completely accurate in the CHF group and in healthy controls due to the limitation of 
the assay detection range (24-1500 pmol/l), resulting in the median value in CHF cats being 
underestimated and in healthy controls possibly overestimated. Also partial NT-proBNP data 
were collected retrospectively (nine cats collected from 2012-2014). As exactly the same 
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techniques were used and both were performed in IDEXX Laboratories, the results should be 
compatible with the new test results from 2017. The APP tests used in the current study were 
newly developed commercial assays. So far, feline APP tests lack standardization; tests 
performed with different methodology in different laboratories may give different values 
(Sasaki et al., 2003). Therefore, the current APP cut-offs should be interpreted with caution for 
future studies if a different assay is used. Also, a dog PCT assay was used in the current study. 
Knowing that APP expression may be species specific, it is difficult to clarify whether the 
varied PCT expression in the current study was a genuine biological feature or due to the 
species difference. Additionally, the timing of measuring the APPs would in theory affect the 
absolute values of current measurements. This is particularly the case for major APPs such as 
SAA and AGP. The cut-off values may be potentially underestimated for those markers. 
Limitations were also present in study design particularly for survival analysis. Some cats were 
euthanized rather than dying naturally, so survival days may not accurately reflect the disease 
severity, as multiple factors are involved in making a euthanasia decision, such as owner’s 
choice. Also, it should be noted there was a discrepancy between initial diagnosis and initial 
blood sampling dates in some cats. Cats that have been controlled with long term medication 
prior to first biomarker measurement may benefit from medication and this might therefore 
mask the intrinsic disease status. Other limitations for the longitudinal study design are 
described in Section 4.6. 
Overall, the current study did suggest SDMA, LRG-1, SAA, ceruloplasmin and AGP could be 
promising novel biomarkers for feline CHF and CM. Given the discussed limitations of this 
pilot study, future work needs to be carried out for further validation.  
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4.8 Final Discussion 
Feline CMs have been recognized for more than 40 years and, the understanding of the disease 
has improved dramatically especially in the last two decades. Prevailing research has focused 
on understanding disease pathogenesis, developing and optimising methods for more cost-
effective diagnosis, management and prognosis. A biomarker study can potentially meet all the 
above criteria and provides an opportunity to see the disease from a broader perspective.  
This study focused on two mechanisms which were hypothesized to be associated with feline 
CMs particularly in the CHF stage: CvRD and systemic inflammation. By evaluating the two 
panels of serum protein biomarkers, it was aimed to answer the following questions: (1) Are 
these two pathophysiological processes involved in feline CM, particularly with CHF? (2) If 
yes, can any of these biomarkers be useful for disease diagnosis, management and prognosis? 
The theory base of CvRD is that in heart disease renal perfusion is compromised secondary to 
low cardiac output and in the acute decompensation scenario, it can cause acute renal injury. 
The neurohormonal activation of the RAAS and SNS which temporarily compensate for 
reduced renal perfusion can in the long term cause adverse consequences (Ronco et al., 2008). 
Cytokines released during endothelial injury and passive renal congestion can also cause 
oxidative injury of the kidney (Pouchelon et al., 2015). Cardiac therapeutics such as loop 
diuretics also lead to GFR reduction and further impair kidney function (Francis et al., 1990; 
Lazzarini et al., 2012). This type of ‘Cardiorenal Syndrome’ has been firstly established in 
human medicine and more recently has drawn veterinary attention. The term cardiovascular–
renal axis disorder i.e. CvRD was proposed in small animal medicine in 2015 by a group of 
veterinary cardiologists and nephrologists (Pouchelon et al., 2015). Studies in the small animal 
cardiology field since then include a few reports on chronic mitral valve disease (Martinelli et 
al., 2016; Choi et al., 2017). To the author’s knowledge, this is the first reported study 
investigating CvRD in cat cardiac disease. 
In the current study, renal functional marker SDMA and creatinine were significantly higher 
in CHF cats compared with controls. Cardiac biomarker NT-proBNP was found increased in 
CHF cats compared with CM cats without clinical signs and healthy cats in a reciprocal manner. 
High SDMA and NT-proBNP appeared to associate with poorer outcome in feline CHF. The 
significant correlations of renal biomarker with cardiac biomarker NT-proBNP supported the 
hypothesis that there was cardio-renal interaction in CHF.   
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The recognition of CvRD in feline CM with CHF is essential, as this would help cardiologists 
to make clinical decisions on whether and when action on protecting renal function should be 
carried out. Renal dysfunction is a poor prognostic indicator in human heart failure (Hillege et 
al., 2000; Hillege et al., 2006), earlier recognition of renal impairment in heart failure patient 
is therefore important, especially when the renal change is reversible. Knowing CvRD has 
developed in certain cardiac patients, clinicians can tailor those patients’ medical treatment 
protocol and add extra consideration for kidney protection. In other words, it allows more 
elaborate control in balancing the two organ systems, which potentially can improve the long-
term outcomes (Orvalho and Cowgill 2017). Traditionally, serum creatinine level was used for 
kidney disease grading, for both AKI and CKD. However, as a renal biomarker, neither 
sensitivity nor specificity of creatinine is ideal (Yerramilli et al., 2016). SDMA is a novel renal 
biomarker and became popular in veterinary medicine recently (Relford et al., 2016). In this 
study, SDMA appeared to be a more sensitive renal biomarker than creatinine, therefore it 
should be added to a renal function monitoring panel in feline CHF management. It should be 
noted that both SDMA and creatinine are considered as renal functional markers. To detect 
early renal injury, more sensitive renal biomarkers are needed. Currently, investigated renal 
injury markers in veterinary medicine include NGAL, inosine, clusterin, cystatin B, kidney 
injury molecule-1, NAG and retinol binding protein (Lapointe et al., 2008; De Loor et al., 2013; 
Bland et al., 2014; Chacar et al., 2017; Orvalho and Cowgill, 2017). These could be useful to 
detect earlier stages of CvRD in the future, and address the kidney issue when it is in an earlier 
reversible stage. 
One limitation in the current study was it did not have a CHF population without medical 
treatment. Analysis of CvRD markers in such a population would be ideal for evaluating 
intrinsic CvRD in CHF in the absence of diuretic interference. However, in a referral practice, 
this is difficult to achieve as the majority of CHF cats have had some medical stabilization 
before they are referred for further management.  
Inflammatory infiltration of the myocardium has been found in feline CM previously (Fox, 
2003; Fox, 2004; Aupperle et al., 2011; Khor et al., 2015), both in asymptomic CM and in CHF 
states. The association between inflammation, the immune system and heart failure has been 
noticed for a long time and, their interaction and mutual cause-consequence relationships are 
very complex (Celis et al., 2008; Dick and Epelman, 2016; Van Linthout and Tschope, 2017). 
Circulating inflammatory mediators carry great value as inflammatory biomarkers in heart 
failure studies, apart from assisting identifying aetiology and pathogenesis, they have potential 
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as disease monitors, prognosticators and therapeutic targets (Bozkurt et al., 2010). APPs are 
good examples; they have been studied extensively in human cardiovascular diseases and some 
of them have showed promising prognostic value in human heart failure (Ahmed et al.,2012). 
In the current study, positive APPs SAA, LRG1 and ceruloplasmin were found increased in 
CHF cats compared with controls. Furthermore, these over-expressed APPs were significantly 
correlated with the cardiac biomarker NT-proBNP, LA size and CHF severity. Interestingly, 
serum AGP stood out in both univariate and multivariate analyses as an independent prognostic 
factor in feline CHF. All these findings supported the fact that APPs play a role in feline CHF. 
It should be noted that apart from serving as inflammatory biomarkers, APPs also have other 
biological functions. For example, LRG1 was found to have a protective effect against adverse 
cardiac remodelling (Kumagai et al., 2016) and ceruloplasmin has been found to associate with 
oxidative stress (Cao and Hill, 2014; Hammadah et al., 2014). These would be potentially 
useful in identifying causative pathological pathways in CHF and to develop therapeutic targets 
in the future studies.  
It should be noted that the APP results should be interpreted cautiously. Because these 
biomarkers are highly sensitive and non-specific, unknown occult inflammatory comorbidities 
may contribute to their elevations (Ceron et al., 2005; Ceron et al., 2008). Also, so far most 
feline APP assays have not been not standardised, which may result in discrepancy in cut-offs 
between different studies (Kann et al., 2012). When used with other clinical information, they 
can be promising biomarkers for feline CHF.  
There are three criteria for assessing usefulness of a biomarker: (1) whether it can be measured 
accurately and repeatable with short turnaround times and reasonable cost; (2) whether it can 
provide additional information to other established clinical assessments; (3) whether its 
quantification can assist in making clinical decisions (Morrow and de Lemos, 2007; Gandhi 
and Pinney, 2014). Serum SDMA fits these criteria as being reasonably accurate and repeatable 
with reasonable cost, it recently became available as an in-house test; it can provide information 
on kidney status that is superior to creatinine. The feline APPs assays currently still need more 
standardization. Serum AGP, SAA and Hp are relatively available. The APPs are useful on 
indicating if there is ongoing systemic inflammation; also they can potentially provide 
information for disease pathogenesis and prognosis. High AGP is a potential novel biomarker 
in predicting survival in CHF cats, although it cannot be used as a sole marker for prognosis; 
test standardization will help to set up accurate cut-offs. In summary, SDMA, SAA, LRG1, 
ceruloplasmin and AGP carry promise as novel biomarkers for feline CHF. 
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One exciting secondary finding was all the examined biomarkers were independent from CM 
sub-phenotypes. This is very useful information which means the biomarkers are free from 
phenotypic dependent bias, which can be a problem considering the current equivocal 
classification system. Several clinical parameters showed their power in differentiating feline 
CM stages and helping prognosis. A multiple assessment approach incorporating clinical 
diagnostic parameters and biomarkers would be interesting to develop in the future. Current 
well accepted heart failure classification systems in small animal medicine include American 
College of Veterinary Internal Medicine (ACVIM) classification and ISACHC classification 
system, however both classifications are not ideal (Pouchelon et al., 2015)-they fail to reveal 
underlying disease aetiology and cannot accurately and sensitively reflect disease severity and 
progression. A combination of clinical parameters, together with biomarkers possibly can give 
a more accurate picture of the disease, for example a scoring system containing clinical 
parameters known to be associated with prognosis, may be more beneficial to get objective 
views of individual animal’s disease status. In human medicine, there are several scoring 
systems for risk assessment in heart failure patients (Ross, 2012; Pocock et al., 2013). A clinical 
scoring system has been developed to assess canine mitral valve disease severity and it 
managed to differentiate the patient groups with different clinical outcomes (López -Alvarez 
et al., 2015). In the future, a clinical scoring system could be developed for risk stratification 
in feline CHF. It would be more objective and helpful to reveal a global picture of the disease 
and would be a more accurate approach for giving prognosis compared with single factor based 
assessment. 
Lastly, it should be clarified that this study primarily focused on CHF rather than CMs. The 
pathogenesis of feline primary CM remains unclear. When the disease is in an advanced CHF 
stage, it further complicates the story. Current understanding of CHF in veterinary field is a 
consequence rather than a cause for CM. In humans, ‘maladaptive hypertrophy’ also called 
cardiomyopathy of overload has been considered caused by heart failure (Katz, 2002).  In a 
failing heart, neurohormonal systems are activated in response to decreased cardiac output and 
increased intra-cardiac pressure. The cardiomyocyte becomes hypertrophied as a response to 
pressure overload and to neurohormonal activation. In the end, evidence of myocardial 
remodelling is seen in any CHF patient, regardless of the primary cause either if it is a primary 
CM or mitral valve dysplasia. Knowing that humans and cats share similarities in many 
cardiovascular conditions, it would not be surprising if similar maladaptive mechanisms can 
occur in the feline patient. This provides extra challenges to solve the puzzle of feline primary 
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CM pathogenesis especially in the CHF case. For feline CM pathology and pathogenesis study, 
pre-clinical stage patients would be interesting to investigate, in terms of getting a clearer idea 
of what is going on in the heart before it gets decompensated.  
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4.9 Future Work  
Apart from potential future work aspects mentioned previously, there are other further research 
directions extended from this project which can be summarized as following:  
(1) Further characterize the prognostic values of SDMA and NT-proBNP in CHF cats. 
Longitudinal monitoring of SDMA and NT-proBNP values in larger number of CHF 
cats could yield more information. A combination of cardio-renal marker profile will 
also be interesting to assess, which may improve the power of disease prognosis.  
  
(2) Investigate other cardiac and renal biomarkers for CvRD. Cardiac marker cTnI 
previously was found to have prognostic value for feline HCM (Borgeat, et al.,2014b), 
preliminary work in the current study also showed the cTnI level was significantly 
higher in CHF cats compared with compensated CM. The cardiac biomarkers cTnI/NT-
proBNP combined with acute renal injury markers would be an interesting direction for 
future CvRD investigation, especially for monitoring acute CHF episodes. 
 
(3) The APPs may be potentially used for disease monitoring and therapeutic response 
assessment. In future longitudinal studies, it would be interesting to see if the up-
regulated APPs LRG1, SAA and ceruloplasmin have differential expressions in 
different CHF stages; if their changes are associated with clinical symptoms (e.g. 
recurrent CHF); if they are responsive to therapeutics. Additionally, pro-inflammatory 
or anti-inflammatory cytokines such as TNF-α, IL-6 might be worth evaluating to 
assess the extent of a systemic inflammatory response in feline CHF (Bozkurt et al., 
2010). 
 
(4) Knowing that apart from serving as inflammatory mediators, the APPs also have other 
biological functions, certain detailed pathophysiological pathways would be worthy to 
investigate for understanding the disease pathogenesis. For example, LRG1 is known 
to play a role in preventing adverse cardiac remodelling via TGF-β pathway in a mice 
model (Song and Wang, 2015; Kumagai et al., 2016), it would be interesting to examine 
the same pathway in feline CHF and develop potential therapeutic targets based on the 
pathway findings. 
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(5) Besides the biomarkers investigated in the current study, there is a bigger biomarker 
galaxy out there for further exploration. Advanced technology such as proteomic 
techniques will be useful for global discovery of the biomarkers in feline CHF and CM. 
In fact, the logical approach of clinical biomarker development is global biomarker 
discovery then followed by verification and validation (Frantzi et al., 2014). A 
proteomic study is therefore a promising future direction for systemic development of 
clinical biomarkers in feline CM. 
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4.10 Conclusion 
In summary, the current findings support the presence of CvRD and systemic inflammation in 
cats with CHF caused by primary CM. SDMA is a promising biomarker in feline CHF and 
should be considered for use in practice for renal function monitoring in CHF management. 
The APPs LRG1, SAA and ceruloplasmin are believed to be helpful in understanding feline 
CHF pathogenesis and AGP can potentially be used as a complementary test for prognosis. A 
combination of clinical tests and biomarkers appears to be a promising future direction for risk 
stratification in feline CHF. 
This study provides new insights into feline cardiac biomarker research and the findings will 
potentially benefit clinical management and prognosis, as well as fundamental research into 
the disease. 
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Appendix 1: Parameters Considered in Univariate Analysis 
 
Animal Information 
Sex 
Age at initial diagnosis  
Body weight 
Echo parameters 
LA diameter 
LA/Ao ratio 
LVFWd  
IVSd  
LV FS% 
Spontaneous Echo Contrast (present or absent) 
Intracardiac thrombus (present or absent) 
Clinical information 
Previous ATE history (Yes or No) 
Overall CHF  status during study (stable or unstable)  
Heart Rate  
Arrhythmia by auscultation (present or absent) 
Gallop sounds (present or absent) 
Heart murmur grades  
Pulse deficit (present or absent) 
Arrhythmia on ECG (present or absent) 
Respiratory rate  
Biomarker Level 
NT-ProBNP  
SDMA   
Creatinine  
AGP  
CRP  
Hp 
LRG1  
SAA  
PCT  
Troponin 
